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I . I NTRODUCT I ON. 
Of a II the ma I i gnant I ymphomas Hodgk 1 n 1 s disease has been studied most 
extensively .. A. clear-cut natural history emerged; this induced nev.· philosophies 
of Treatment, 1,.1hich resulted in a better survival (Kaplan, 1972; Clinics in 
Haemato I ogy, ~: I). 
The other malignant lymphoMas, a larger group, have not been studied as 
thoroug i y, It seems there·fore aoprop irate to aoo I y to these I ymohof'1as the 
oroved techniques, which have been used for the study of Hodgkin's disease. 
By this method their subtypes, natural history and resemblance to Hodgkin's 
d: secse may appear. 
The clinical data of 314 patients with a r",al ignant non-Hodgkin 1 s lyrrphoma 
have been studied, using Rappaoort 1 s histological classification and the 
Ann ,A,rbor staging method. It is the largest study in the Netherlands 
originating from one single institute. 
The fol ioh'ing points have been studied especially: 
-the prognostic value of Rappaport's histological subdivisions, 
- the orognostic value of the Ann Arbor staging classification, which has been 
originally developed for Hodgkin 1 s disease. 
- primary symptoms and signs. 
-frequency of concurrent neoplasms. 
the frequency of extranodal primary sites, their prognosis as compared to 
nodal origins. 
-method of spread: contiguity, mediastinal skipping, therapeutic consequences. 
-results of treatment: overall and detailed per type of treatment. 
- side-effects of treatment. 
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complete remission: its quality expressed as the product of frequency and 
duration, interrelation of the durations of subsequent remissions. 
-local recurrence. 
frequency of bone marro>tl invasion. 
- the prognostic significance of cl inicai and therapeutical data, their 
importance alone or in combination with others. 
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II. SELECTION OF PATIENTS, DATA HANDLING. 
The studied material consists of a review of the case history and biopsy 
r;,aterial of 314 pa-tients seen at the Rotterda:<~ Radiotherapy institute 
( ~, q_. T, I . l . 
THE PATIE1\JTS. 
Years of st~. 
The pa·rients ·,._,ere seen for the first time in the years between 1950 and 
1971. The closing date of the study was August 1st, 1973, which means a minimum 
foi low-up oeriod of 2 years and 7 months. 
The patients in this study reoresent about one third of the total number 
of patients with a malignant lymphoma who were seen at the institute during 
the time of the study (Annual Reports R.R.T. I .l. The total number of patients 
v1ho entered the study per annum is given in Fig. 2.1. 
totaal n = 314 
20 d n""' 166 
15 
':(. n = 148 
10 
5 
year of presentation 
Fig. 2.1. : Number of patients entering the present study per annum. 
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Patients lflere excluded from the study ·~1hen it was not possible to obtain 
the original biopsy material for review within four months. 
Referra I area. 
The R.R.T.I. is the largest oncological centre in the Netherlands, 
.,.Jhere at present about 2.600 ne·N patients are seen each year; of these about 
135 have a ma i i gnant I yrr,phoma. The referra I area is Rotterdam and suburbs 
'-'lith about one mi II ion inhabitants; many patients '.\'ere also sent from 
secondary centres throughout the country. 
Reasons for inclusion. 
f\.11 0atient records vlith a diagnosis of non-Hodgkin 1 s lymphoma from the 
study period were drawn from the files. In each case it was tried to recover 
the biopsy slide from which the original diagnosis had been made. These slides 
were 1 bl indly 1 reviewed by J.A.JVI. van Unnik, who is the consultant pathologist 
in this field for the European Organisation for Research and Treat~ent of 
Cancer in the '.Jetherlands. If the reviewing pathologist could not confirm the 
diagnosis of malignant non-Hodgkin 1 s lymphorw, even after new 11:icroscopic 
slides were made from stored material, the patient was Of')itted from further 
study. This occurred in 21 cases. 
2. DATA HANDLING. 
Relevant information from a case history, ~1as noted on specially 
orepared optical reading charts {Apoendix Al. Later on these 1,vere converted 
into punch cards. The data on these cards \\'ere stored on comouter background 
memory. Appendix 8, which is a translation of Appendix A, shows which factors 
were considered relevant and the code 1vhich was employed. 
Punchcard No. 1 contains the basic unchanging information about the 
patient, this can be easily updated. 
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Cards 2 and 3 together represent the first episode of the iII ness. 
A second episode is recorded on a new set of cards 4 and 5 which resemble 
card 2 and 3; subsequent episodes on 6 and 7 8 and 9 , and so on. This makes 
it pass i b I e to record a II reI apses separate I y. Not rnore than three episodes 
have been analysed. The criteria of the Ann Arbor conference {Carbone, et al ., 
1971; Rosenberg, et al., 1971) have been used for staging: Table 2.2. 
I. InvolveMent of one single lymph node region (1 ), or of a single extra-
lymphatic organ or site (IE). 
II. Involvement of two or more lymph node regions on the same side of the 
diaphragm {Ill, or localized involvement of an extralymphatic organ and 
of one or more I ymph node regions on the same side of the diaphragm (I IE). 
Ill. Involvement of lymph node regions on both sides of the diaphragm (Ill), 
which May also be accompanied by localized involvement of an extra-
lymphatic organ (II IE), or by involvement of the spleen, or both. 
IV. Diffuse or disseminated involvement of one or more extralymphatic organs 
or tissues with or without associated lymph node enlargement. 
A \'IIi thout symptoMs. 
B With general symptoms: 
1. unexplained weight loss> 10% in 6 months. 
2. unexplained fever. 
3. night sweats. 
Table 2.2: Staging criteria of the Ann Arbor Conference, 1971. 
- 5 -
Complete remission means no signs of activity on physical or X-ray investiga-
tion~ also the E.S.R. has to be below 30 mi I im. in the first hour. Partial 
remission means significant improvement. 
The computations were done on an I.S.M. computer (Type 1130). As exact 
information on the computing programs is given in detai I in Appendix C, only 
a general outline is given here. All data v1ere checked for errors (e.g. 
incorrect data, staging errors, wrong dates) by special programs. After 
correction the final calculations were made, using a system 1~hich made cross 
tabulation possible up to seven dimensions. 
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I I I. PATHOLOGY OF NON-HODGKIN'S LYMPHOMAS. 
1. BRIEF HISTORICAL REVIEW. 
The first description of lymphoreticular tumors was given by Hodgkin in 
1832 and subsequently by \\1i lks in 1865. A part of the cases described by them 
would, by modern standards, be classified as ngenuine Hodgkin 1 s disease 11 , 
another cart as cases of non-Hodgkin's lymphomas. 
Later on the existence of malignant lymphomatous disease differing from 
lymphatic leukemia and Hodgkin 1 s disease was described especially by Virchow 
(1858, 1863) thereby introducing the clinical entity 'lymphosarcoma' 
(Billroth, 1871). 
The distinction between Hodgkin's disease and the other malignant 
lymphomas was more precisely drawn by the work of Kundrat (1893), 
Dreschfeld (1893), Paltauf (1896), and especially by Sternberg and Reed, 
who called attention to the characteristic giant cell of Hodgkin's disecse 
11898 and 1902). 
Beside the typ i ca I I ymphosarcoma there was a I so recognized a type 
consisting of cells cytologically more resembling reticular or reticulum 
ce! Is; this type was finally named reticulum cell sarcoma by Roulet (1930, 
1932) after having been given a great variety of names Wberl ing, 1928; 
Ghon and Roman, 1916, Goormagchtigh, 1926). 
A period followed in which a confusing chaos of names (Willis, 1948) 
emerged, because many pathologists proposed a new classification. However, 
each classification only remained useful In the hands of its originator. 
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After the recognition of the giant fol I icular lymphoma as a separate 
entity by Br i I I ( 1925) and Symmers ( 1927), there emerged in 1966 from the 
11 haooymarriage'' (Gall, 1958) between cytologic views of Gall and Mallory 
(1942), and the concept of nodular versus diffuse lymphoma of Raopaportft 
et al. (1956) a final classification by Rappaport (1966). This widely used 
classification is used in the present study. After the classification of 
Rapoaport on I y a few rare separate types of I ymphoma have been described 
(Rosai and Dorfman, 1969 and 1972; leading article Lancet 1973, Frizerra, 
et al., 1974; Lukes and Tindle, 1975; Schultz and Yunis, 1975; Rappaoort 
and rv!oran, 1975). 
2. RAPPAPORT'S CLASSIFICATION (19661. 
This classification is based on two sets of criteria: 
1. the pro I iteration patters in the lymph node. 
2. the cytological type and its degree of differentiation. 
2.1. Pro I i ferati on patterns. 
It is presumed that each cytological type- v1ith the exception of the 
undifferentiated tyoe- may present itself in a diffuse or a foil icular form. 
Instead of the term foil icular the somewhat confusing equivalent nodular is 
used too. The fol I icular malignant lymphoma is distinguished from the 
'reactive' lymph node according to criteria laid down by Rappaport, et al. 
( 1956). Usua II y the fol I i cuI ar type progresses to the corresponding diffuse 
form in the course of the disease (Hurst and Meyer, 1961; Dorfman, 1964); 
and also the cytologically mixed types have a tendency to become more 
histiocytic. 
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2.2. Cytologic type and degree of differentiation. 
Rappaport distinguishes between lymphocytic and histiocytic lymphomas, 
each with varying degrees of differentiation -also a mixed type consisting 
of both ce II types exists: 
Well differentiated lymphocytic lymphoma. 
This type consists of rather small, mature, uniformly appearing 
lymphocytes, which are hardly distinguishable from normal lymphocytes. One 
should be careful to distinguish this lymphoma from its systemic morphological 
counter-part: chronic lymohocytic leukemia. Some of these tumors produce 
monoclonal immunoglobulins (Kim, et al., 1973). 
Poorly differentiated lymohocytic lymphoma (P.O. Ly Ly). 
The lymphocytes in this tumor show varying degrees of nuclear atypia, 
immaturity and high mitotic activity. It is felt (Berard and Dorfman, 1974) 
that the classification poorly differentiated is too broad, and that in this 
category finer subdivisions should be made. In children the lymphocytes often 
resemble those of acute lymphoblastic leukemia, but in adults this is seen less 
often. Adults mostly disolay: 1) r10re differentiation in cell size, 2) small 
cleaved cells {foil icular centre cells according to the Lukes terminology, 
1974), 3) 11 leukosarcoma cellsn in the bone marrow and/or peripheral blood (see 
Schnitzer, et al., 1970). In children the foil icular pattern is extremely 
rare in contrast to adults.: however progression to leukemia occurs more 
often (SuI I ivan, 1962). 
It shou I d be kept in mind that the d i sti ncti on between we II d i fferen-
tiated and poorly differentiated lymphomas is in essence an artificial one, 
and serves for convenience only. Some investigators are testing the value of 
further morphologic subdivision, especially in the poorly differentiated 
class (Van Unnik, 1973). Also differentiation in the degree of nodularity 
probably has practical use (Patchefsky, et al., 1974). 
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Histiocytic lymphoma (H Ly). 
This consists of neoplastic histiocytes in various stages of maturation 
and differentiation, sometimes with phagocytosis and/or 11 fibroblastic'' 
differentiation. The spectrum may range from the poorly differentiated forms, 
to the well differentiated type. The poorly differentiated forms are 
characterised by: 
al more or less round nuclei 
b) rather prominent eosinophi I ic nucleoli 
c) scanty cytoplasm. 
The well differentiated type shows one or more of the following features: 
al deeply indented or oval nuclei 
b) abundant, and often eosinophi I ic cytoplasm, with phagocytosis 
c) increased reticulin forr:1ation. 
Undifferentiated lymphoma (U Ly). 
This is formed of pleomorphic cells without any appreciable histiocytic 
or lymphocytic differentiation: large nuclei containing a delicate chromatin 
structure and one single distinct nucleolus, and varying amount of cytoplasma. 
The cells may seem cohesive. Sometimes the term 11 stem-cell" has been used 
for these cells, but this term imp I ies a non-existing potential (Maxi mow and 
BlooM, 1942). 
Mixed (lymphocytic histiocytic) lymphomas (M Lyl. 
This group includes mixed forms of lymphocytic and histiocytic lymphomas, 
they are mostly follicular. 
3. CLASSIFICATION USED IN THIS STUDY. 
Based on Rappaport's classification some minor modifications (Van Unnik, 
1973) were made by J.A.~~. van Unnik who reviewed all material of the patients 
under discussion. 
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al The lymphocytic types are not subdivided in well differentiated and 
poorly differentiated, but- according to cell-size into small, intermediate, 
large, and polymorphocellular lymphocytic. The small lymphocytic type which 
corresponds with Rappaport's well differentiated lymphocytic lymphosarcoma is 
cal led lymphocytosarcoma (l.C.S.l and the remaining types together are 
ca II ed I ymphob I astosarcoma ( L. B.S.). 
bl The mixed lymphocytic- histiocytic type is considered as lymphocytic 
{as done by Dorfman, 1974). 
c) The others are divided into histiocytosarcoma {H.C.S. l, i.e. Rappaport's 
histiocytic lymphomas, and histioblastosarcoma (H.B.S.l, an expression from 
Math8, et al. ( 1970). 
dl The foil icular mixed group was considered apart because of its special 
interest. This classification is only used when lymphocytes and histiocytes 
are equally represented. 
e) The division into diffuse and follicular is in accordance with Rappaport's 
method. Partial follicular is considered as follicular. A problef'l has arisen 
due to the retrospective nature of the present study. In soMe cases it was 
i mCJoss i b I e to obta 1 n adequate I y stained s I ides for deterrni n i ng the presence 
of toll icular structures or to obtain the original biopsy material. Because 
special reticulin stains were not always avai I able only H.E. stained slides 
were used for determination of the structure. The problems arising thereby 
are discussed later. 
In the actual data extraction more detailed subdivisions 1vere made-
which have not been used in this study, but remain avai I able for later 
studies. The computer has rearranged these subdivisions into the present 
classification. For comparison Rappaport's classification is shown in 
Tab I e 3. I. 
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As the histological classification is made on the first diagnostic 
slide, two histological aspects have not been studied. These are: 
a) the similarity of multiole biopsies done at the same time, 
b) the similarity between subsequent biopsies during the course of the 
disease. They have not been studied, because mul~iple biopsies have been 
done in a I imited number of oatients. 
Rappaport, 1966 Present study: v.Unnik, 1973 
Well differentiated lymphocytic LCS = Lymphocytosarcoma 
Poorly differentiated lymphocytic LBS = Lymphoblastosarcoma 
Histiocytic HCS = Histiocytosarcoma 
Undifferentiated HBS = Histioblastosarcoma 
Diffuse Diffuse 
Nodular/Follicular Follicular 
Follicular mixed Follicularmixed 
Diffuse mixed -Corresponding lymphocytic type 
Table 3.1. :The classification used in the present study compared 'Nith 
Raopaport's class1 ficaY1on. 
4. RECENT DEVELOPHENTS IN LYHPHm1A CLASSIFIC.ATIONS. 
U I trastructura I studies of the respective morpho log i ca I pr-esentations 
anc.1 functions of the lymphocyte and histiocyte and their place in the normal 
ly~ph node, and data obtained froM immunological and functional studies, 
have resulted i1 considerable further developments (Hansen and Good, 1974). 
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The norma I I ymph node. 
A brief review of the structure and function of the normal lymph node 
is necessary in order to understand subsequent classification of tumors 
originating from lyr1ph nodes which are nin fact all -more or less 
caricatural ly- derived from their parent eel Is'' (Diebold, 1970). 
4. 1 • The norma I I ymph node. 
The lymph node starts with an afferent lymph vessel. which enters at the 
subcapsular sinus. From there on the lymph may pass through the maze of 
interfoll icular sinuses to the marrow sinus, or through the lymph foil icles. 
The i nterfo IIi cuI ar tissue consists of a network of 11 marrow-macrophagesn, 
which show much pinocytosis and phagocytosis (Ned. Ver. voor de lmmunologie, 
197il. Surrounding the lymph follicles is the parafollicular zone consisting 
of small lymphocytes. The foil icles do not exist in germ-free animals 
(Humphrey and Frank, 1967; Akazaki, 1973), but are formed by the antigenic 
stimulus of the normal environment. 
The follow'1ng types of cells have- as yet- been distingu'1shed in the 
lymph foil icles: 
a) Desmosome-bearing reticulum cells forming together a reticular structure 
by means of desmosomes ( Lennert, 1964; Lennert, et a I . , 1966). They form the 
majority of the follicle, in which they arrive and fuse together from their 
diffuse spread throughout the lymph node, after the first exposure to 
infection. These dendritic macrophages (White, 1963) trap the antigen, not by 
real phagocytosis, but by surface binding faci I itated by opsonins (Nossal, 
1967; Nos sa I, et a I . , 1968). It is supposed that the I ymphocytes, which pa'ss 
from the parafoll icular zone along these antigen-laden dendritic reticulum 
cells, pick up a message to transform CNossal, et al., 1968; Lukes and 
Coli ins, 1971) into large blast I ike cells. 
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bl Normal phagocytically active macroohages (settlers from the phagocytic 
system) v1hich may contain phagocytosed nuclear remnants. 
cl Foil icular centre cells or gerMinal centre cells, whose exact origin is 
not yet cor:~pletely clear. It is thought that they are transformed 6-lymphocytes, 
which got instructions on their way to the geminal centre from the dendritic 
11 reticulu1'1 cells"~. Once they are triggered by some antigenic stimulus, they 
undergo transformation in the foil icular centre to large blast I ike cells of 
the same light-microscopic appearance as stimulated lymphocytes. 
The different types of lymphocytes and reticulum cells have an important 
function in the immune resoonse. 
4.2. The lymohocytes. 
They are divided up into B-lymphocytes and T-lymphocytes with different 
origin and function, although in close coOperation (Keuning, 1972). 
al The imrrunoglobul in carrying B-lymphocytes may be transformed into large 
blast I ike cells in the germinal centre, which are called germinoblasts by 
Lennert, 1964. They are morohologically identical to the cells observed in 
irritated lymph nodes, which are called non cleaved cells by Lukes and 
Collins (1971). Lukes and Collins (1974) distinguish between five separate 
morphological steps during this transformation: small lymphocyte, small 
cleaved cell, large cleaved cell, small non cleaved cell, and finally large 
non c I eaved ce II. They a II transform in the parafo I I i cuI ar areas of the 
lymph nodes (Van Buchem, 1962; leading article Lancet, 1974) into plasmacells. 
During their transformation they are already oroduclng antibodies (Gowens 
and Knight, 1964; Oort and Turk, 1965). In vitro this transformation is 
especially stimulated by pokeweed (Raitt, et al., 1969). 
bl The T -lymphocytes, which form rosettes with sheep erythrocytes, are 
located in the deep cortical areas. 
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They are respons i b I e for the ce II u I ar immunity; they sometimes he I p the 
B cells in starting immunoglobulin synthesis O~ulder, 1972J; they also 
respond to PHA stimulation. Some lymphocytes never show the characteristics 
of B- or T-lymphocytes.; they are called null cells. 
4. 3. The ret i c u I um ce I I . 
There has always been some uneasiness about the term reticulum eel I 
sarcoma; some people thought that it was being misused as a '!wastebasket'' for 
poorly differentiated malignant neoplasms of lymph nodes (Butler, 1970); 
others thought that it encompassed different types of ce II s: '~true" hi sti o-
cytes, and lymphocytes, which resemble histiocytes because of special 
Influences (see 4.2). Instead of Ashoff 1 s {1924) unitarian concept and its 
later versions (Cline, 1973) a different concept of the 11 retlculum cell" has 
arisen (Van Furth, 1970). Now this cell is divided into two groups. The 
first consists of the mononuclear ohagocytes, including the monocytes and 
their offspring which have settled In the tissues: histiocytes, Kupffer cells 
and macrophages. The other group consists of cells belonging to the 
connective tissue, e.g. fibroblasts. The dendritic reticulum cells of the 
germinal centre have not yet found a place In any category (Diebold, 1970). 
4.4. Recent trends in malignant lymphoma classification. 
As all tumor types -more or less caricaturlcally- resemble their 
parent ce I I, new c I ass if I cations based on the newer concepts of ce I I u I ar 
origin have been attempted. 
It is now clear that the former reticulum eel I sarcoma Cor histiocytic 
lymphormsl contained the following cell tyoes: 
a) Lymphocytes in transformation, l'lhether B-, T-or null-cells. 
bl Oesr1osome-bearing dendritic reticulum cells. 
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c) Poorly differentiated fibroblasts ( 1!structured elements 11 l. 
d) A remnant of poorly differentiated other tumor types with lymph node 
metastases. 
This concept stems from studies by Stein, et al. (1972l, Levine and 
Dorfman (1974), Dorfman (1974), and ~~ennemeyer, et al. (19741, who show on 
the basis of enzymocytochemical, ultrastructural, and immunological studies 
that many reticulum cell sarcomas do not originate from reticulum cells 
at all. Foil icular lymphomas are thought to originate from B-lymphocytes on 
the basis of immunologic cell markers (Shevach, et al., 1972; Jaffe, et al., 
1974; Hansen and Good, 1974l and the presence of dendritic reticulum cells 
(Levine and Dorfman, 1974). The large and small follicular centre cell 
produce the fo IIi cuI ar I ymphoma (they are ca II ed germi nob I ast and germi nocyte 
by Lennert, 1964). The occurrence of the true reticulum cell sarcoma, which 
consists of dendritic reticulum cells, and the occurrence of true lymphocytic 
follicular lymphoma are rare (leading article Lancet 1974). However not all 
authors agree on the assumption that all follicular lymphomas are of B-cell 
origin (Peter, et al., 1S174}. 
It May similarly be presuMed that a regrouping of the diffuse lymphomas 
~li II take olace in the near future when the exr.lct origin of the malignant 
lymohocytic cell has been more firmly established (Seligman, 1974; 
Gaji-Peczalska, et al., 1973; ~~ichlmayr, et al., 1974; Piessens, et al., 
1973). Attempts in this direction have been made by Dorfman (1974; 2 papers), 
Farrer-Brown (1973), Gerard Marchant, et al. (1974); however they were based 
on I y parti a II y on these new data. Another attempt was made by Lukes and 
Coli ins, who consider the various subtypes of the transforming B-lymphocytes 
in the toll icular centre as the origin of foil icular lymphomas. About the 
diffuse lymphomas and the T-cel I lymphomas they have no definite opinion. 
- 16 -
At presenT Rappaoort 1 s classification is the only useful clinical guide 
(Bradfield, 1974). 
5. PATHOGENESIS. 
The exact oathogeneti c mechanism is st i I I unkno11n. Probab I y a I ymphol'la 
cell is iTiggered into malignant degeneration by a multitude of influencing 
factors- although the exact place and importance of each of ther:1 is sti II 
being debcted. 
The most irnoortant fac7ors are probably infectious agents and genetic 
fac-1-ot-s although both may seem to be geographic factors (Freeman 1 et al., 
1972; Danti, et al., 1968), the latter because of the fact that the same 
susceptible genes are common in the whole oooulation of that area. The 
genetic 'factor may be expressed in a spec.ial tissue antigen composition. 
or ]::.paired imr"une response of autoimmune disease (Cummings, 1971). It may be 
possible that an infectious agent, for instance a virus (0Mochowski, 1970; 
Gerber 1 et ai ., 1972) induces sor1e change in the lymphocytes, probably with 
the hsi~ of other unk;no\'in factors (Ramboud and ~vlatuchansky, 1973), in a 
susceptible individual who does not have the oroper immunological defence-
v1hether the fault be congenital or acquired (Penn and Starzl, 1972). Lukes and 
Cell ins (1974) suppose, that in the case of the B-cell lymphoMas, a block 
or dereoression somewhere during the transition from smal I lyMphocyte to 
large non ·::le'Jved follicular centre cells exists. 
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v~i~ICAL FEATU~ES AND HISTOLCGY. 
1.1, Presenting ~omp!aint. 
fhe first single spontaneous co~p:aint, which after proper evaluation 
cou!d Qe asci-i bed to the ly!:iphoma is I isted in Table 4, 1 .. lA fev,· remarks about 
_,.his table are the fol ic·,Jing: 
a. aJjorrina! complaints: these enco~pcss a very wide spectrum such as 
dbdominal masses. a change i~ Dowel habits, gastric problems, etc. 
etc. 
c. resp 1 ~-a Tory symotor~s: dyspnea, hemoptoe, etc 0 
d. it should be noted that complaints about constitutioni:il symptoms in this 
·rable ere only those ~lhichwere spontaneously told; later \Table ~.3) the 
results o"" e:x:pl !cit questioning· ir; this regard are gi'len. 
7 he chief oresenting complaints are pai,less lymphadenopdthy, E.~.T. 
pr-oblei':S, ac:d a~dor:inal complaint~~. These are follo'cmd at a distance by skin 
abnormal r-,"ies and no coMplaints, the lest of 'elhich me3ns thai- the disease 
was discovered accidentally. 
Tnese results v1ere comparea 1·1ith tr.ose of Rappaport, et 21. (1956l, 
Rosenberg, et al. (19G1), ~-}lolander and Pac!<. (1963) end !bbott, et al. (1966). 
Raopaport's cases, v1hich also contain 18 nudular sclerosing for11s of Hodgk1n 1 s 
disease, are all follicular; he has only noted the chief compla;nt instead of 
the first corrplcint. In lbbott 1 s cases, · .. ,!hid, are all lymphocytic, all first 
sr:o·roms rave been noted. The fact that scme patients have r1ore than cne 
first syMptom explains the totai of more than one hundred per cent. The 
comparison is given in Table L.2, which shmlS their data in a similar way as 
has been done in this study. 
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Presenting complaint Percentage 
of 
Tot c?' 0 + 
Total 
None 8. 3 26 1 0 16 
Lymph node enlargement 35·7 1 1 2 63 49 
I 
Painless J2.8 1 OJ 58 45 
1 Painf'ull 2·9 I 9 5 4 
Abdominal complaints 1 J. 7 I 43 23 20 
Fatigue-malaise 2o5 8 5 I 3 
L Fever 0.6 2 1 
I 1 
I Skeletal pain 1.9 6 4 2 I 
\,ieight-loss 0. u. c. 0 0 0 0 
I E.n.t.-problems 21 0 6 68 30 38 
I V. cava. syndrome 0.3 1 0 1 
Hespiratory symptoms 2.5 8 7 1 
Skin-lesions 6.7 21 1 1 10 
Salivary glands 0.3 1 0 1 
1
.Jrogen:i tal complai.nts 1.9 6 4 2 
I 
~.fuscle weakness O.J 1 0 1 
Unkno1-lll 3·5 1 1 6 5 
Total 100 
"' I' 
314 166 148 
Table4.L A survey of the presenting comolaints. 
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I Author !Rappaport I.B. Batt ! Rosenberg Molander Present 
' 1 966 1966 1 1 961 1963 study 
' Total 
I number 247 107 1269 567 314 
None 6 6 
I 
8 
Unknown I 10 21 I 4 6 I 0 
Lymph node-
I 57 52 64 I 46 36 enla:rgement 
1 
I ! i 56 ,' Painless 55 I 33 ' I i 
' ' 
' i I I ' ' i Pain:full 2 8 I 3 I I 
Abdominal 
complaints 9 8 21 20 1 4 
I Fatigue 
malaise 10 15 14 3 
Fever 4 5 5 11 1 
I Skeletal pain J 2 I 
I 
I 
\>'eight-
loss o.u. c. 8 9 1 5 0 
' E.N.T. 
1, problems I 22 ' 
~Vena ccva 
syrtdrome 1 
Respirato-
, ry symptoms 8 J 11 9 3 
i Skln-lesions 2 J 7 
i ! ' L __ 
:3ali7ary 
I 
' I ' gl<Lnds 1 
' 
' Urogen-cial 
' I 
I 
complaint I 2 i 
Hu.scle 
weakness 4 1 I 
Table 4.2. Presenting complaints in the I iterature, expressed as percentages. 
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Not1,Jithstanding the sampling differences, here too the enlarged lymph nodes 
are the most- frequent coMplaint, follm1ed by abdominal distress. Only the 
E.N.T. probleres show a definitely higher frequency in this study. This may be 
caused by the fact that others have not filed these under the heading first 
complaint b~t included them in the first localization, or by the fact that 
the codperation with the E.N.T. surgeons in the Rotterdam are~ is very 
intensive. In other studies the involvement cf Waideyer's ring is a relatively 
fr-ecueno occurrence too; e.g. R.osenberg, et ai. (1961) 7,4 %, Jones, et al. 
(1973) 2% (follicular '/pel and 1'1% (diffuse type), Lattuda and Milani 
( 1973! 11 %. The relatively low frequency of comolaints about constitutional 
sympTor-1s is CJrobab! y caused by the fact that on I y the very first camp I a i nt 
has been noted and a closer questioning about systemic symptoms was made later. 
1 .2. Constitutional symptoms. 
Constitutional or systemic symptoms (fever, sweats, weight lossl occur 
in 25% of ai I cases: Tabie 4.3. The total number of patients in this table 
is 267 instead of 314, because r;1any patients could not remember exactly, 
even after pertinent questioning. This is in accordance \'lith the literature 
Ylhich states percentages ranging from 14% (Lattuda and l'~i lani, 1973) to 25% 
{Rosenberg, et al 0' 1961; r··1 olander and Pack, 1963). Probably the real value 
of the occurrence of systemic symptoms I ies in its orognostic significance 
(jones, 1974). This wi II be discussed in chapter 8: "Factors influencing 
.. 3. Primarv !ocaiization, nodal vs. extranodal. 
The pr-imary localization is most often found in the lymph nodes~ as can 
be seen in Table 4.4. 
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! 
I 
-ymptom-=: 0 do to._ j 0 
" + 
0 I 
' 
0 
I 1 05 96 201 
I 
75 neg. I 
pos. I 41 25 66 25 I 
total 1 46 1 21 267 I 100 
Table 4.3. Frequency of constitutional symptoms. 
D tot --$~» 
Nodal I 66 65 131 
Nodal and extranodal 74 57 lJ! 
Extranodal I 23 .,8 41 
Leukemic transform, 2 4 6 
Total 165 144 J09 
Table 4.4. ; Frequency of primary localizations. 
42,5 
42 < i ·~ 
1J I 
2 
100 
185% at least 
J noda2. component 
13% extranoda 1 
only 
This can be expected in a I ymphornatous disease; however the percentage of 
primary organ localizations is quite high in contrast to Hodgkin's disease 
( Kap I an, 1972), The extra nod a I occurrence of 13 % over a I I is in agreement wi ~ 
the data of Lattuda and ~nlan! (1973): 10% of 556 cases, Banfi, et al. (1962 
11 ~~of 300 cases, ~osenberg, Jiarrm-,d :::nd Jaslo>iiitz (1961): about 15% of 12C 
cases, end 12% of 405 cases (Jones, et al. 1973). it is however somewhat 
less thar, described b-" i' 1!ciander, et al. (1963): 31% of 567 cases, and 
considerably less than the figures given by Peters, et al. (1968), which vary 
from 40% of 631 cases (lymphosarcoma) to 61 %of 270 cases (reticulum eel 
sa rcorna ) . 
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Primary localization wi II be discussed later with regard to pathology 
and other factors. 
1.4. Primary localization, detai'l-..ed. 
A survey is given in Fig. 4.5 (all data in this subdivision are derived 
from ,A.ppendix D)_ Comparison with data from the ! iterature enforced these 
different presentations. because Many authors used different ooints of view 
when discussing the same problem. in Table 4.E -rh~ data are compared \11th 
·thossof studies by Rosenberg, et al. {1961)., ?ete•s, et al. (1963), 8anfi, 
e+ al. (1972) and Lattuda and ~·'!ilani (1973). :t should be noted beforehand, 
that comparing these figures with those cf earlier studies can be ~isleading 
because of the differences in diagnostic refinements avai I able to the 
respective authors- e.g. the rise in bone-marrow positivity is a function 
of samol ing technique and number of punctures (Jones, et al .• 1972). Never-
theless, ',~hen comparing these data with caution, some similarities do appear. 
The adenopathies figure very strongly with cervical lymph nodes occurring most 
frequentiy; the f,-equenc(es of the other lyf'lph nodes are sti II in doubt_, but 
signi"ficantiy less. They are closely followed by primary localizat-ions in the 
skin, gastro-intestinal tract, resoiratory tract and bone-marrow-alI others 
see~ to be infrequent, 
The frequencies of nodal and extranodal initial sites in their respective 
category are compared v.fith tr<e literature in Table 4.7. This table includes 
authors, '·,Ji-:c ore not present in Table 4.6., ~ecause not all have data on all 
asoecTs, e,g~ Freem-an, et ai. (19721 oresen-1- data on extranodal localizations 
on I y. R.egarc 1 ng the I vrr,oh r;odes there seems to )e a good agreement or, the 
relative frequency, except for the frequencies of positive spleens and 
abdominal lyr:1ph nodes in Banfi 1 s series. 
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!eft neck 
right neck 
woldeyer 
left ox! I Ia 
left groin 
right axn~a 
right gro~n 
mediastinum 
skin 
spleen 
liver 
abdominal lymphnodes 
upper airways 
bone morrow 
stomach-duodenum 
lungparenchymo 
urogenital organs 
skull 
pleural exsudote 
endocrine organs 
small intestine 
salivary glands 
0 
c:::::::::J 
F'''''''''''''''' 
,,,,,,,,,,.,., .. 
lliTl 
EJ 
[ill 
IEl 
0 
D 
D 
~ 
Fig. 4.5. : Frequency of primary localizations. 
w 
0 
01ote the shaded boxes represent organ localizations, the others 
nod a I I oca I i zati ons. 
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Author j Rose""- Pe- Pre 
-
-· ~ 0 - -
I "berg ters da sent 
I Date ' 1 961 1963 1 973 study 
' I i 
Total ' 1 269 nr. 901 556 .314 
' 
LE Neck } t 1 4 h? >37 22 RI Neck 
' 
1 4 Lf4 
LE ~LI_,"<C:illa 1 ' 5 23 >9 l 5 
J 
,, 
RI Axilla J 5 21 
LE Gro:in l 'I 
" 
l 22 I 
>12 ' 1 1 I 
' J RI Groin j 4 20 
1\'a ldeyer 7 1 0 1 1 25 
Mediastinum 3 2 4 1 7 
Spleen ? 1 1 1 5 
Abdominal lyno ? 6 1 5 1 2 
U.R.I. ? ? ? 8 
Esophagus ? 1 ? 0 I 
I 
Stomach 2 
f 
? 6 
16 
I 
Sm" Intestine 1 ? 2 
J Colon 0 ? 0 
Liver 0 0 3 1J 
Skin 
I 
5 6 5 1 6 
I Skeleton 4 4 1, 4 I 
I 
Lung :;?arench. I 0 1 2 6 
I ! Ple<:.ral exsud" 0 ? 1 
" 
5 
Bone-]\iarro1J ? 8 
? 2 2 
Endocrine glands ? 0 2 
Table 4.6. Frequency of orimary localizations in the literature and this 
study. 
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I 
! 
Author 
w w 
- ~ ..; ~ ~ 
'" ~ 
'" 
~ 
-
~ .. .. 
" 
- '" '" 
~ 
~ 
'" '" 
0 ond 
" " "' "' 
' ' -
-
~ 
.0 ~
~ ' 
' ' "" ' 
' 
0 ~ ~ 
" 
" 
~ 
' ' ' 0 0 0 0 
" ~ ~ ~ ~ ~ date 
1269 567 102 53 314 Total number of patients 
38 24 37 31 37 Cervical 
9 16 21 20 18 Axillary 
3 4 5 7 7 Nediastinum 
12 11 18 17 17 Inguinal 
nd nd 2 2 6 Spleen 
nd 7 17 24 5 Abdominal 
nd = no data 
Table 4-7~ Distribution of initial 
lymphadenopathy in percentages 
Xote: Involvement of \'ialdeyers ring is 10% in the 
present study, it is not mentioned seperctely in 
the other studies. 
~ Author N ~ ~ 
ro ~ ~ 
" 
'" "' 
~ 
" "' - -
ro 
-
= 0 
" 
ond 
" ' 
~ 
' 
" 
' 
" ' 0 
" " 
" 
0 ~
' 
' " 
0 
" 
date 
" """ 
~ ~ 
418 1467 163 314 Total number of patients 
! 24 nd 7 Stomach 
35 8 nd 3 Intestine 
' 6 nd 0 Colon 
' 1 nct 12 18 Liver 
12 8 16 21 Skin 
9 5 13 5 Skeleton 
2 }_. 7 8 Lung 
nd nd 6 Pleural exsudate 
6 nd nd 11 Hespiratory tract 
nd nd 4 6 Urogenital organs 
nd nd 11 11 Bone marrow 
4 5 6 2 Salivary glands 
2 4 1 2 Endocrine glands 
nd 16 nd 0 Other 
Table 4-72 : Distribution of initial extranodal 
presentations in percents 
nd no data 
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Fig. 4.8. Frequency of single presenting sites. 
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In the extranodai presentations ·rhere is I ittle doubt about the predoMinance 
of the skin, the gastro-intestinal tract (most frequently the stofT1ach), 
resoiratory tract and bone-Marrow. Finally, in order not to be confused by 
the Many primary sites present at the same Ti~e in one patient, one may wish 
to look at the real primary sites (as far as can be ascertained clinically) 
by considering the orimary sites in stage I only CFig. 4.8). There is very 
i itt I e comparison pass i b I e ··rl i th other studies. On I y the study of Scheer 
(1963) is coMoarab!e in this respect. Other studies, who consider this, have 
usea the Rye staging classification, which has a different interoretation of 
stage I. As snown in Table 4.9 the frequencies of nodal presentations are 
similar; about extranodal presentations nothing meaningful can be said 
because both series are too srr,all. 
2. CLIN!CAL STAGE. 
The cl inica! stages of the p::;tients according to the Ann Arbor- scheme 
(2arbone, et ::11., 1971; Rosenber-g, et al., 1971) are given in Table.4.10. 
It should be noted that in this material some oatients wer-e not staged as 
sophisticated as they would have been nowadays. In the ear-lier years notal I 
diagnostic methods, which are considered necessary today, e.g. lymphangio-
graphy and laparotony U~oran, 1973; Jones, et al., 1974; Fer-guson, 1973J ·~1ere 
used. This 'fliil pr-obably have resulted in some understaging (Veronesi, 1974), 
as these h1o procecures are especially useful for- diagnosing involvef'lent of the 
snleen, ~ar-a-acrtic and mesenteric lymoh nodes. A compariso~ with data from 
Lattuda an.J l'·ili!ani (1974), and .Jones, et ai. (1974) does not re""1der essential 
differences except fo~ a dip in stage I I I in the present series. This is a 
consistent feature of the Rotterdam material, because almost the same frequency 
of stage Ill v1as also seen in an earlier- study (Vander ~lerf-Messing, 1968) 
on other oatients fr-oM the same institute. 
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Source ~cheer 1963 Present study 
Total number 130 70 
of patients 
Neck LE } 31 15 Neck RI 1 7 
Axilla LE } 10 3 Axilla RI I 1 
Groin LE } 7 5 Groin RI 1 
-h'aldeyer 1 1 1 1 
l'Iediastinum 3 5 
Spleen 1 
U.Resp.Tract 2 5 
Stomach 10 1 
Skin 1 2 
Skeleton 3 
Pleural exsud. 1 
Lung parench. 3 
Urogential organs 3 
Salivary glands 1 
Endocrine glands 2 1 
Table 4.9. Frequency of single orimary sites, in percentages. 
total number 
Author I II III IV of patients 
Jones, 1 974 10 25 25 40 405 
Lattuda, 1971+ 27 37 25 1 1 556 
Patchefsky, 1974 48 62 293 
Present study 23 36 10 29 31 1 
Table 4.10. :Frequency of clinical stage, in percentages. 
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3. HISTOLOGY. 
3.1. Cell type. 
The distribution is given in Table 4.11. Both sexes are equally 
represented in the total series of 314 patients except for a male predominance 
in H.C.S. 
3.2. Structure. 
Table 4.12. In this table the total number is 221, because for this 
study only H.E. stains were used, on which it is not always possible to give 
an opinion about structure. All cases where the structure was doubtful were 
orr.itted here. This may have caused some underrepresentation of the foil icular 
type, because a concurrent prospective series in the Netherlands, in which 
alI sections were seen with reticulin stains, gives a slightly higher 
percentage 34% CVan Unnik, 1973) instead of 25 %. 
In the oresent series diffuse lymphoma affects Males considerably more 
otten than females. There are 3.6 times as many men in the diffuse than in 
the foil icular group (96 vs. 26) but only 2.3 times as much diffuse women 
(69 vs. 30). This difference is in agreement with the findings of others 
(Gall and Mallory, 1942; Jones, et al., 1973). The reason for this is sti II 
a matter of speculation. In the foil icular type the sexes are equally 
distributed (Dorfman, 1964). 
1,\lhen these results are compared to those of Veronesi, et al. (1974) and 
the augmented series of Jones (1974) there does not seem to be much agreement: 
in the present series the lymphoblastic variety is rather frequent and in 
Veronesi's series the histiocytic type predominates: Table 4.13. 
- 30 -
Numbers Percentages 
J 0 tot J' 0 tot + + 
LCS 44 42 86 53 47 100 
LBS 61 61 122 50 50 100 
HCS 39 22 61 64 36 100 
HBS 1 8 20 38 47 53 100 
FM 4 3 7 57 43 100 
Tot 1 66 148 314 53 47 100 
Table 4.11. Distribution of cell types. 
I~ e Diffuse Follicular Both 1 n % J' 0 n % t 0 n % J' 0 + + -> 
. 
LCS 21 40 13 8 32 60 1 7 15 53 100 30 23 
LBS 85 83 49 36 17 1 7 6 11 102 100 55 47 
HCS 38 93 22 1 6 3 7 1 2 41 100 2J 18 
HBS 21 84 12 9 4 1 6 2 2 25 100 1 4 1 1 
Total 165 75 96 69 56 25 26 30 221 100 122 99 
Table 4.12. Cell type and structure. 
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Structure Diffuse Follicular 
Author 
_,. e, _,. e, 
['-
"' 
['-
"' 
"' " "' 
0
_,. ~ +' ~ ~ +' 
['- CJ] ['- CJ] 
"' 
"M 
"' 
"M 
~
" 
+' ~
" 
+' 
0 
" 
0 
" w 
" 
0 w 
" 
0 
0 0 ill 0 0 ill 
Cell 
" 
H 0 
" 
H 0 
type 0 0 H 0 0 H 
"' 
> 
'" "' 
> 
'" 
LCS 3 7 1 0 1 6 14 
LBS 20 7 38 37 1 0 8 
HCS 28 54 17 7 1 9 1 
HBS 4 0 1 0 4 0 2 
Total 55 77 75 45 33 25 
Table 4.13. Cel I type and structure as perc~ntages of the total 
number of patients in different studies. 
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This also occurs in another series from the same institute (Lattuda and 
Mi I ani, 1974) in which the histiocytic type amounts to 66 %. It should be 
noted that ir, this caomparison the mixed cell type has been included in 
the L.B.S. class (poorly differentiated lymphocytic lymphoma), which is 
common practice nowadays. 
3.3. Presence of macrophages. 
Table 4.14. The presence of large pale reticulum cells containing 
predominantly nuclear debris is thought to be a prognostic index. These cells 
first studied by Diamandopoulos and Smith (1964) who Identified them in 10% 
of reticulum cell sarcomas using Rappaport 1 s classification. However, they 
felt that the distinction between histiocytic and undifferentiated was 
often so subjective that it should be omitted. Their findings are co~oarable 
to the 8.5% in the present series 1-1hen H.B.S. and H.C.S. are combined 
together. The large-cell variety and the diffuse structure most often 
contain macroohages. Multiple regression analysis wi II show that their presence 
has a distinct prognostic influence (see chapter VI I I). 
3.4. Concurrent neoplasia. 
It has otten been stated (Gunz and Angus. 1965; Hyman, 1969) that 
oatients with lymphoprol iterative disorders have more chance to develop 
other malignanci3S 1 but htere are at least as many authors (Moertel, 1957; 
YVatson, 1953; Berg, 1967; Warren and Ehrenreich, 1944) who deny this 
increased incidence. 
~ost patients have, once their lymphoprol iterative disorder has been 
discovered, an excellent follow-up, which favours early detection. 
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Negative Positive 
Cell-type nr % nr % 
LCS 71> 90 9 1 0 
LBS 102 84 1 9 1 6 
HCS 58 97 2 J 
HBS J1 82 7 1 8 
Total 265 88 37 1 2 
Structure 
Diffuse 1J9 85 25 15 
Follicular 60 97 2 J 
Total 1 99 88 27 1 2 
Table 4.14. : Presence of macroohages. 
Second Percentage 
tumor of total 
" '" 
number 
·o • 
"' 
.:1 
" 
+' 
0 
Lympho-
rna type 
LCS n ~ 86 4 1 5/86 ~ 6 
LBS n ~ 122 2 5 7/122 ~ 6 
HCS n ~ 61 0 1 1/61 ~ 1 
HBS n ~ 28 0 0 0/28 ~ 0 
FM n ~ 7 1 2 3/7 ~4o 
Total n ~ 314 7 9 16/314 ~ 5 
Table 4.15. Occurrence of a second tumor. 
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1Nhen this influence is el ininated by comparing them with a group having 
a simi la1 intensive foiiO'd-uo U1oertel, 1957; Berg, 1967) the ·Incidence of 
cancer is about the same as in the general population, except for malignancies 
of the skin, The frequency of the latter .• most often in the form of basal cell 
carcinoma, is about tenfold higher than normal. It is not celar whether this 
is due to the same carcinogen, or to the loss of immunologic function 
(Hyman, 1969), or to the effect of ootential ly carcinogenic treatment. 
In the present series, in which the oatients have a I ifelong follow-up, 
five per cent developed anotr,er malignancy after the diagnosis of malignant 
non-Hodgkin 7 s lymohoma: Table 4.15. In view of the intensive and long 
follow-up this does not seem to be an important rise in frequency. It is 
not c I ear whether any va I ue must be attached to the fact that most nel'.' 
ma I i gnanc i es arise in the I ymphocyti c types; an exp I a nation cou I d be that 
the patients with the more malignant histiocytic types did not I ive long 
enough to develop other malignancies. 
4. BONE-HARROW INVASION. 
Fifty eight per cent of the oatients with initial stage IV had a 
bone-marrow evaluation by aspiration. Tumor inti ltration was seen in 36 per 
cent. In the diffuse lymphoma there is a higher frequency of bone-marrow 
invasion than in the foil icular type: 67 vs. 22 per cent: Table 4.16. It was 
felt that further subdivision of each cell type in its structural variants 
would produce unrealistic percentages because of the very small number in 
each category. 
From Jones, et al. (1972, 1974) and Dick, et al. (1974) ''1'18 know that 
the chance of finding of marrow invasion by a marrow aspiration is only half 
of that when more aggressive techniques such as Westerman needle bone biopsy 
or open surgical biopsy are used: 8 per cent vs. 16-18 per cent. 
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positive negative total 
N % N % N % 
LCS 10 67 5 33 15 100 
LBS 3 14 18 86 21 100 
HCS 3 33 6 67 9 100 
HBS 0 0 3 100 3 100 
FM 2 67 1 33 3 100 
Tot 1 8 36 33 64 51 100 
Foll 6 22 21 78 1 7 100 
Diff 8 67 4 33 12 100 
Tot 14 36 25 64 39 100 
Table 4.16. Bone-marrow invasion in stage IV. 
Age M F Tot 
0 - 10 3 4 7 
10 - 20 6 2 8 
20 
- 30 9 4 13 
30 - 40 12 7 19 
40 - 50 21 21 42 
50 - 60 33 25 58 
60 - 70 39 35 74 
70 - 80 31 34 65 
80 - 90 10 1 4 24 
90 -100 2 2 4 
Total 166 148 314 
Table 4.17. Age at presentation. 
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The percentage of positive bone-marrows in aspirations from a II stages 
is 8 · this consists of 18 stage IV patients with bone-marrow i nf i I trat'r on 
and 6 with leukemic development. 
The overall yield of 8 per cent positive results is derived from only 
38 per cent of the total number of patients. Abou-t the distribution of the 
oosilives over the pathology types no firm opinion is possible because the 
-rota I figures are too sma I I. 
5. AGE AND SEX. 
Table 4.17. In contrast with moste authors (Rosenberg, et al., 1961; 
lattuda, et al., 1974; Lee, et al., 1973; Molander and Pack, 1973; Hansen, 
1969; Molander, 1965; Jones, 1973) who state a male/female-ratio ranging 
from 1.5-2 to 1, the sexes are about equally distributed in the present 
series, 53 per cent are men, and 47 per cent are women. It is tempting to 
see the equal distribution of the sexes in the present study as specific 
for Northern Europe. However, a smaller study carried out at the same tir:1e 
at the Dutch Cancer Institute in Amsterdam (Hart, 1973) gives a percentage 
of 60 per cent men out of ~ total of 126 patients. The age distribution of 
the age at presenTation is in close agreement with the I iter·ature. There is 
a pred i I ecli on for the I ater dec~ des in both sexes. The average a.~e for 
V1omen is slightly nigher than for men (55.2 years vs. 51.6 years). 
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APPENDiX D. 
A review of "the Mos"t important orimary localizations cross-tabu:ated 
against stage, oathology, structure a~d sex. 
Notes on Apoendix D. 
The column t·Dtals may exceed 314 because Many patie:--rts had m\Jit:ple 
oresen~i~g priMary sites. 
L. The coiu:--1r1 totcls may be less r:,an 314 (e.g. in 11 s·i·ructure~') because on 
some oatie~ts there are no data avai I able about the aspect under 
,:iscussion. 
3. Ther-e a:e 24 positive bone-marrows of IY~rich 18 are stage IV; the ot~,er 
6 are of course stage IV too, but are subclassified in the grouo 
ly:'"i')horrra >slth leukeMic develoornent. 
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V. FURTHER CLINICAL INTERRELATIONS. 
1. STAGE, CELL TYPE AND STRUCTURE. 
The reI ati on bet\veen ce I I type and structure has a I ready been discussed 
(see Table 4.3}. It remains to be seen whether any histology subclass has 
a tendency to skip stages. This would suggest a rapid, probably haematogenic, 
disseMination. in contrast with the orderly soread along the lyMphatic path-
>.~ays (Goffinet, et at., 1973) that has clearly been established in hodgKin 7 s 
I ymphor:1a ( Kap I an, 1972). Most authors subdivide the patho I og i c materia I in 
two para I lei series according to structure. Although the value of the 
structural division cannot be denied, in this study both possibi I ities are 
considered as the ends of a structural spectrum and the aspect of structure 
is treated separately. 
1.1. The relation between cei I type and clinical stage is shown in Fig. 5.1 
(see also Appendix El. It is hard to find comparable groups in the I iterature 
because in most series the Rye staging classification or pre-Rappaport 
histological classification has been used. In the series of Jones, et al. 
( 1973) -see Table 5.2- stage IV is more frequent than stage Ill. This is 
esoecially true for the histiocytic type. Although the studies of Lattuda, 
et al., and Patchefsky, et al. (1974) are recent, they cannot be used for 
comparison because the stages are grouped together. In the present sTudy stage 
I I I is also underrepresented as compared with the other stages. This may be 
explained as a tendency for quick generalization from localized to disseminated 
forms. However, comparisons should be made with care because in small numbers 
a large percentage shift can be caused by a few patients. Therefore it seems 
best to conclude only that there is a trend, of early non-lymphatic, probably 
hematogenous spread. 
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% 
100 
LCS LBS HCS HBS 
80 
n = 84 n = 122 n = 61 n = 37 
60 
40 
1 dJB 20 Gl{J dJdJ 11 
Fig. 5.1. Cell tyoe and clinical stage. 
Source Jones 1974 Present Study 
Stage I II III IV I J:I III IV 
Cell type 
LCS 25 12 1 9 44 21 28 17 35 
LBS 12 21 30 37 22 40 9 29 
HCS 1 1 32 19 38 24 33 7 36 
HBS 60 40 1 0 0 24 57 3 1 6 
Fig. 5.2. Cell type and clinical stage in the I iterature. 
_ L~o _ 
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n = 161 n = 62 
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'0 j 1D -· I n ' I ' 
40 J j 
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20 f-
II Ill IV II Ill IV 
Fig. 5.3. Structur-e and clinical stage. 
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F·ig. 5.4. ~ Cell type and structure per stage. 
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1 .2. Table 5.3 shows the frequency of diffuse and fol I icular structures in 
each stage (see also Apoendix F). It seeMS that the distribution between 
diffuse and fol I icular in the different stages is of the same order except 
tor stage I I I, which however consists of a smal I group of patients. 
1 .3. The rather equal distribution of the diffuse and nodular types over al 
stages ~akes the factor str~cture uniMDortant when the distribution of 
histology (eel I type and structure together) over the stages is cons;dered: 
:able 5.4. 
Summarizing we can state that in the present series: 
The oercentage of diffuse I y structured I ymphorr:as in each cyto I og i c tyoe is 
the same in a! I stages. This may indicate that the aggressiveness of the 
diffuse t'jpe is the same cs that of the foll"1cula\ t'jpe because otherwise 
one of the tv1o 1·1ould predominate in the higher stages. 
!he fall ic.'!ar tyoe is infrequent and occurs from 10 to 20 per cent, exceot 
far tne ~.C.S.-variant where it is oresent in 60 per cent. 
T~ere is a tendency towards early dissemination compared with the spread in 
r.odgk in 1 s disease because there the frequency of stage I I I and IV together 
is lovver (Kaolan, 1972). 
2 AGE, CELL TYPE, STRUCTURE A~C STAGE. 
2,' The d i stri "outi on of the c:e I I types over the age groups is shO' ... TI in 
Fig. 5.5 (see also Appendix Gl. 
it is apparent t.'lat the lyrnohocytic t'jpes are evenly spread over the 
Cifferent age groups, 1-1hereas the histiocytic types seem to be rare below 
the age of twenty. A I I cyto I og i ca I tyCJes have about the same average age 
at the time of diagnosis: 55 years. 
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Fig. 5, 5, Ce I i type and age. 
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Fig. 5.6. Structure and age. 
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2.2. Foil icular structures are evenly distributed over the different age 
groups, as shown in Fig. 5.6. The percentages range around 25 (see also 
;l,ppend i x HJ. 
Data from the literature (Rosenberg, et al., 1961; Lee, et al., 1973; 
·'·~olander and Pack, 1963; Hansen, 1969; Gal i and r'1iallory, 1942; Lattuda, 1974; 
Patchefsky, et al., 1974) agree 'l'ifith the results of the present study; they 
shovJ the same foequency curve, 't~hich is similar to the age distribution of 
most malignancies (Ackeoman and del Regato, 1970), but different from the 
bir,odal age distribution curve in Hodgkin 1 s disease U~cMahon, 1957). This 
difference suggests a pathogenesis which is different from that of Hodgkin!s 
disease. 
2.3. Fig. 5.7 demonstrates that within each stage the age distribution is 
similar except for stage I I I, which shows an unexpected peak in the years 
from fifty to seventy and a relative deficit after that. As it does not 
seem 11 ke I y that a certain stage can be detected ear I 1 er at a certain age, 
the stage/age distribution should follow the age distribution. The reason 
why stage I I I shows a different distribution Is probably the fact that in 
this reI at i ve I y sma I I group a few pat·l ents have caused d i sp roporti on a I 
oercentage shifts. 
The average age for all stages varies from 51 to 56 years. 
3. PRI,~ARY LOCALIZATION, CELL TYPE, STAGE. 
The clinical stage at first presentation gives some information about 
the primary localization. Study of the frequency of extranodal primary 
localization in each cytological category gives additional data. It shows if 
a cell type has a tendency to start extranodally. 
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%of stage in a 
certain decade 
80 
70 
D--O stage 1 n "' 70 
.lk---d. stage II n = 113 
e----e stage \II n "' 32 
lm---iliil stage IV n = 85 
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I 
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Fig. 5. 7. C I in i ca I stage and age. 
Cell tot a 1 nodal extra both , leuke-
type number nodal mic rr 
' 
LCS I 85 I 40 1 2 43 5 
i LBS 120 43 1 5 40 2 
! HCS 6i 
I 
JJ 15 52 0 
I HBS J7 62 1 1 I 27 0 ! 
Table 5.8. ?requency of primary site within each cytological grouo 
in percentages. 
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It may be argued that the same conclusions can be derived from the 
construction: "'eel I type vs, str-ucture vs. stage vs. prir-:ary local 'zation'' 
as v1as done by Jones, et al. (1973). However the totcl nur:ber of patients in 
the present study does not a! io>.•l such a four-dimensional division because the 
grou~s become too sr:al I for realistic interpretation. 
Table 5.8 shows the freouency of nodal and extranodal primary si7es for 
each eel I tyoe. It appear-s that there :s no preference for an extranodal 
s"talt in any of t:-,e cytological types. The frequency of about 13 per cent 
extranodal primary sites is in agree~ent with the data of Jones, et al. (1974). 
4. CCNSTITUTIOr~AL SYHPTOHS, STAGE AND CELL TYPE. 
The frequency of constitutional symptoms rises sharply with the clinical 
stage, as is shovm in Fig. 5.9.A. There is no significant difference betv1een 
the 0ercentage with B symotoms in the different cytological classes: Fig.5.9.8. 
Therefore it may be concluded that within each cytological class t(le patients 
with constitutional symctoms are concentrated in the higher stages: Fig.5.9.C. 
Only a few remarks are Made in the I iterature about the frequency of systemic 
synotoms in different stages of cytological groups (Hansen, 1969; Jones, 1974) 
but no-thing definite is known. The importance of constitutional symptoms 1 ies 
in their prognostic significance. Some people (Jones, et al., 1973) regard 
them as unimportant subsidiaries of the clinical stage; others (Bloomfield, 
et al .• 1974; Patchefsky, et al ., 1974) think that they have independent 
prognostic significance. In the present study (see chapter: Factors influencing 
prognosis) the presence of constitutional symptoms also emerges as an 
independent orognostic factor-. 
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Fig. 5. 9. 
A: Constutional symptoms and stage 
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II Ill IV 
so 
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B: Constitunional symptoms and cell-type 
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Constitutional symptoms, stage and cell type. 
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VI . TREAF~ENT OF NON-HODGKIN'S l YHPHONAS. 
I . INTRODUCTION. 
The modern treatment schemes for Hodgkin's disease cannot be aop I i ed to 
the non-Hodgk1n 1 s lyMphomas (McElwain, 1974). The latter lymphomas show a 
less CJredictable spread, they are usually more disseminated, and they tend 
-especially in the lymphocytic variants- to involve bone-Marrow earlier. 
Sorne of the localized lyrlDhomas are curable with adequate irradiation, others 
hO'dever hcve cer-toinly, but as yet undetectably, sorend more 1videly, and need 
rr:ore ex·tensive treotment, e.g. chemothoYapy after irradiation (Peckham, 1974). 
Somehow a certain natural aggressiveness of each turner-type has also to be 
takerl into account in the treatment (Kim and Dorfman, 1974). At present many 
different opin:ons are presented about the treatment of non-Hods;kin's 
I Y~"''~homas. HC1'1ever, rnost studies are of I itt 1 e va I ue because they do not give 
infor~ation about histology criteria according to ~appaport, exact radiation 
schemes, or the .A.nn ;\rbo< staging. ~·.·1oreover the total number in each S:.Jbgroup, 
',I' hen modern c I ass if i cation is used, is often so sr;a I: that surv iva I curves 
become statistically insignificant (Jones, Kaplan, et al., 1972). Therefore 
possible prog.'lostically favourable groups can rer:1ain unnoticed. 
2. SY:;:VEY OF T~EAT"IENT HETHODS. 
The thera~y concept at the Rotter·dam Radiotherapy Institute is to ·~Teat 
locoregional disease with radiotherapy, and surgery when neeced. 
Cisseminated disease is treated with chemotheraoy sometimes together ·~1ith 
radiotherapy and/or surgery. The role of surgery as a single !reatment is 
1nslgnificant. Locoregional disease May be translated as cl irtical stage I and 
II, whether A. or 8. Disseminated, means stage IV or leukemic degener·ation. 
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The treatment of stage Ill has oeen variable, sometimes in a case with 
I iMi ted stage Ill disease only rad i atherapy has been given without subsequer1t 
chemotherapy. A survey of treatr:1ent is given in Table 6.1. 
Irradiation type ortho mega mepro "0 toto! 
2 3 2 3 2 3 2 3 2 3 
First attack chemo + 0 5 5 14 15 2 3 0 11 11 2 32 34 
n = 314 chema- 2 62 64 22 110 132 2 32 34 13 9 22 39 13 252 
total 2 67 69 23 124 147 13 20 37 13 20 33 41 245 286 
Second attack chemo + 0 3 3 0 8 8 0 2 2 0 24 24 0 37 37 
n = 184 chemo - 0 35 35 58 59 0 10 10 5 25 30 6 128 134 
total 0 38 38 66 67 0 12 12 5 49 54 6 165 171 
Third attack chemo + 0 2 2 0 5 5 0 0 0 0 20 20 0 27 27 
n = 99 chemo- 0 21 21 0 25 25 0 17 18 64 65 
total 0 13 23 0 30 30 0 37 38 0 91 92 
Note: 1 ""a!so surgical treatment 
2 = no surgery 
3 = total 
Table 6.1. : A survey of treatment. The number of patients receivin~ a 
certain form of radiotherapy {ortho = orthovo I tage, 
mega = megavoltage, mepro = megavo!tage with ~'prophylactic 11 
extended fields) is given for each attack; concurrent cher10-
therapy and/or surgery are also indicated. 
2.1. Radiotherapy. 
Orthovoltage was most often used in the earlier years. The Cosage was 
about 3000 roentgen in 3 to 4 weeks. Later high energy irradiation or mega-
60 
vo I tage was app I i ed, supp I i ed by a Co -source or a I i near acce I era tor. The 
dosage was 4000 rads administered in 20 fractions during 4 weeks- or 
equivalents. 
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The megavoltage irradiation, with the sarr·e dosage, was sor;etimes electively 
apol led to the surrounding area or adjacent ly~ph node stations too. 
P··legavoltage irradiation w:th anc without elective 11 proohylactic 1' irradiation 
are abbreviated as mega respective I y mep ro in the i I I ustrat i ens. The exact 
irradiation data have partly been pub I ished elsewhere (Van der Werf-Messing, 
1968}, the other data will be published in 1975 by the E.O.R.T.C. 
2.2. Surgery. 
Surgery varied considerably in scope from a siMole tumor excision or a 
diagnostic exploration, to extensive oall iative laparotomies. Surgery ,,..,as 
used in 13i% of all cases, in 3t% it was the only form of treatment. In 
the rerr.aining 10% it was palliative. 
2.3. CheMotherapy . 
. All oatients were treated in the time before the more powerful (eye I leal l 
chemotheraoe·~·t i c combinations caMe into use in the R. R. T. I . Treatment consisted 
~ost often of single sequential chemotherapy sometimes concurrent with 
corticosteroids in high dosage. As can be seen from Table 6.2 alkylating 
agents, corticosteroids, procarbazine, and vinca alkaloids \'Jere most frequently 
used. 
3. RESULTS OF TREATMENT. 
3.1. Overal I results are depicted in Fig. 6.3. The number of patients in each 
group is given in Table 6.1. 
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A!kylating agents 
~itrogen mustard 21 
ChloraMbucil 6 
Cyclophosphamide 24 
Triethyleen melamine 2 
Vinca alkaloids 
Vincristin 
Vinblastin 
Hethotrexate 
Corticosteroids 
B I 8011'-YC i n q 
6-1'-'1ercaptoCluri ne 
Daunomycin R 
Procarbazine 
Urethane 
Tota I number 
3 
28 
4 
2 
5 
99 
Table 6.2. Sum~ary of chemotheraoy. 
% n=314 
100 Condition at end of study: 
.;- by campi ications 
90 2 ·r by tumor 
80 3 t by other cause 
4 t by unknown cause 
70 5 complete remission 
60 2 
6 oartial remission 
50 
40 
30 
20 ~ 10 3 4 
Fig. 6.3. : Results of treatr1ent. 
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The results must be interpreted 1vith some caution, because in the patients, 
·who >.vere entered into the study I ate, the fo I I ow-up may have been too short. 
This might make the survival figures only slightly worse, because the minimal 
follow-up is 2~ years and most patients in whom the disease was fatal died 
within three years. \1/ith a therapeutic approach of predominantly regional 
megavoltage irradiation, and single agent chemotherapy as practised at that 
time at the R.R.T.I., 66% of the patients (Fig. 6.3) die with non-Hodgkin 1 s 
lymphoma. The three and five year survival Dercentages (Fig. 6.4) are about 
37 and 25% respectively. Comparable and almost similar data are given by 
Rosenberg, et al. (1962) in their very extensive study. 
80 -
60 -
MF 
40 - ~ 
M:. 
20 -
I I 
' 
2 3 4 5 
years of survival 
Fig. 6.4. Three and five year survival of males (MJ and females (FJ, 
expressed as percentages of their numbers at the beginning of 
the study. 
- 52 -
The surviv31 data are comparable with those of Molander and Pack (1963), 
>.'<'ho had almost the sar;,e therapeutic concept. It is aoparent from this 
study, that non-Hodgkln 1 s ly~phoma has a high mortality rate. 
3.2. The result of each specific treatr;,ent type. 
The percentages of complete remission, partial remission, and 
theraoeutic tal lures for alI single treatment forms (orthovoltage, 
megavo I tage, meg avo I tage ""' i th extended 1'p rophy I act i c 1' fIe I d ~ chemotheraoy, 
and surgery). 
percent 
90 
' 
80 -=complete remission I 
--=partial remission 
I I -·-=failure of therapy 70 I 
I \ \ l =first trea1ment I I 2 = second treatment 60 \ I I \ \ \ \ 3 =third trea1ment 50 I I \ \I \/ ·I ~ I 
40 
'\ I I 1\ I I I i \ I 30 I I \ I ;I 
20 
I ~ II l ortho \ me~ mepro I j surgery 10 '· I ._.._ I i I ' ' i 
' 2 3 2 3 l 2 (3) 2 3 2 (3) 
Fig. 6.5. : Effect of each single treatment per relapse. 
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3.2. 1. ~adicthercpy. 
There anpears a trend (see Fig.6.5) of inoroving ~esults (~igher 
frequency of complete remission) as the irradiation gets ~ore aggressive 
(voltage, extension of ir,volved fields) Ho'dever, it should be borne in 
rr i nd that tr,e change from orthovo I tage -ro rregavo I tage i rrac! i at ion 
coincided with imnroved diagnostic tools. Therefore understaging in the 
ort~ovoltage time is a distinct possibi I ity - with the conseque,ce of 
u,certreatment. The better result of prophylactic extended field irradiation 
is in son-.e contrast 1vith the findings of Jones, et ai. (1973) anc also 
.... ·ith results of the latest ~.O.R.T.C. trial (January 1975). 
It becomes obvious that the effectiveness of irradiation decreases 
'"the treatment of relapses because orevious radiotherapy may i (mit 
irradiation fields and/or cosage. Therefore the initial treatment should be 
of maxirral curing ootency because a secane attempt at cure (here expressed 
as the oercentege of comclete remissions at each relapse) is much less 
effective. 
3.2.2. Surgery. 
This is rarely (see table 6. i l used as a single treatment, in fact 
only for the excision of very smai I local lesions. As a purely local treat-
r:-ent it r:as a high succes rate (83% complete remissions, see Fig.6.5). 
Therefore :Jrimary surgery may incidentally be performed for the treatm~nt 
of some sma I I stage 
by i rrad i at ion 
3.2.3. Cherrotherapy. 
lymohomas. At present it would probably be follmved 
The results of sequential single agent chemotherapy are poor, because 
complete remission !s only obtained in 18 per cent (see Table 6.5). 
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Wit~ the saMe agents used in about the sa~e frequency, Jane~, rosenberg, 
et al. {1972), ar.d r·.-':onfardini, et al. (1973) obtained cornoarably io\'.' rates 
of- 17 and 20 per cer;t. These results are v10rse than those obtaine·j '""itt. 
intermittent or con+inuous multiple chemot~erapy by Hcogstraten, et al. 
{1973), Luce, et al. (1971), Bagley, et al. ('1972), and Stein, et al. 
(197tl: they achieve about sixty per cent co~piete re~issions. It is clear 
tnat srnsle agent cheMotherapy wi! I be of very minor imoortance in the 
future. 
Therapy can also be evaluated against survival, as has been done by 
Many a·.Jtnors (Lee, et al., 1973; p .. 1onfardini, et al., 1973), 'eihen they 
discuss ::Jarticular forms of treatment. These data are usually o7 I ittle 
value becaus·e they have been derived from nonrandomized studies or beccuse 
they comoare different and incomparable forms o~ treatment (e.g. high 
voitage irradia~ion, which is only used in the favorable lovver stages, with 
multiple chemotherapy, ·~vhich is used in disseminated disease!. Ho'"''ever, i" 
Fig. 6.6 alI single (first! treatments are evaluated agairst survival. 
4. RESPONSE DIFFERENCE PER CELL TYPE. 
f,s shown in Fig. 6.7, it was possible to achieve over 50% cor:.plete 
renissions at the first treatment, with the larger cell types ~arking the 
upper I i mit; the fa i I ure rate ~'-'as about the same for a I I . The r, i gh rate 
of cure in tel I icular mixed lymphoma once more proves that this type of 
lymphoma is an outsider. 
These data may give the imoression that the cell type does not 
significant I y i nf I uence the curab i I i ty of a non-Hodgkin 1 s I ymphorna. 
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- =complete remission 
--=incomplete remission 
--- = fai !ure of therapy 
1 = first treatment 
2 = second treahnent 
3 =third treatment 
Ho1,1ever, the camp I ementary factor of disease-free time after treatment, 
i.e. duration of remission, must be taken into account also, because it 
gives another incication of the curabi I ity (see bel mil. 
Tab 1 e 6.8 shows that the treat~ent response of eac~ ce! type 1 s 
cifferent, when it is reia+ed to the duration of co~olete renission . 
. C.S. e~erges quite gcod, and t~e ~istiocytic variants s~ffer setbac~ 
fol! ·c~lar va~ia~ts attain more an~ :o~ger re~issio~s . 
. ~search was made fo~ a re!ationshio between the duration of +he 
··rsT and se~ond reMissions, as i+ aooeared that the second com~ ete 
re~issio:1 ·./as m~ch longer then the first. It could oe su:Jpcsed -~hat a 
long first comp!ete remission oreaicts a lcng second comoiete remission, 
oecause tne tur·ation of the first re~ission is an i~dicetion of the 
relative benignity. The relation between the duration of the second 
:omplete remission and the curatio~ of the first is ~iven in -able 6. 10. 
-here is no clear relation je~ween the remission duratiors in the oresent 
:;.m:::ll .series. There are no date in the I iterature sbo'Jt a relation bet'.,·een 
the s~bsequent remission durations. 
Cell ·t·ype LCS LBS HCS HBS F)-1 
n total (=l 00~£) 86 1 22 61 JS 7 
;:~ in remi s sj_on 
8ft2l': month 30 1 2 1 0 1 1 1 4 
2 rr;:onths 1J 5 7 J 1 '-1 
J 8 J 0 0 
4 2 J 
5 0 2 
6 2 
7 0 0 
Table 6.8. Juration of first complete remission, related to cell type. 
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Structure Diffuse Follicular 
N total (=100%) 1 65 63 
"' 
,, i:n remission 
after: 1 month 1 2 27 
2 months 5 1 3 
3 2 6 
I+ 2 3 
5 1 2 
6 1 0 
7 0 
:able 6.9. Duration of first complete reMission, related to structure 
Duration of first 
remission in months: <1 1 2 
Total number (=100%) 1 28 26 1 1 
Percentage in second 
renli ssion after 1 month 49 58 51, 
2 months 40 58 45 
3 28 42 J6 
4 21 35 36 
5 1 3 35 1 8 
6 8 27 1 8 
7 8 15 0 I 
8 6 1 5 
9 5 1 2 
10 3 12 
1 1 2 0 
1 2 0 
:able 6.:0, Relation between duration of first and second coMplete remission 
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6. LOCAL '1EClRRENCE. 
The recurrence rate in regions, which had received adequate irradiation, 
is shown for each cytological and structural type in Table 6.11. The 
histiccytic variants do much worse in overall frequency and in reappearance 
time, as shown in Table 6.12. This can be an indication that they are more 
aggressive or that they require a higher irradiation dose than the lympho-
cytic variants. Difference in structure is not an iMportant factor. 
although the recurrences appear earlier in tfie diffuse type than in the 
foil icular tyoe. i,~lhen the data of Fuks and Kaplan (1973), 1vho have rous-iy 
the same irradiation ohi losophy, are compared with the results of the 
present study, it aopears that the recurrence rates are about the same, 
'Hhei"her leaKed at per cell type, or per structure variant (see Table 6.13) 
They also note, cs does hansen (1969), a quic'< recurrence. ;he ve<y quick 
recurrence of ti',e histiocytic variants occ'Jrs in their series too. 
In general it can be said that local recurrence a~pears more ofte:~ 
ana earlier in the histiocytic variants. There is no difference in -rhe final 
total beh,een diffuse and foil icular structures, but in the diffuse type 
tecurrence is faster. 
recurrence none n 
I LCS 25 % 75 % 
-
84 
I LBS 1 9 oi' 81 d ...-1 20 
I 
I' I' 
HCS 27 % 73 " 
-
60 10 
I HBS 3l> % I 66 
d 
-
38 
I 
I' 
FM 0 of 100 d 
-
7 I' I' 
n tot = 73 236 309 
diffuse I 22 1b 78 16 +-162 
' ' follicular I 1 9 % 81 ifl 
-
63 I ;o 
' 
n tot = l.J-8 177 225 
Table6.11. Frequency of I oca I recurrence 1 n reI ati on to ce I I type and 
structure. 
- 59 -
Appearance 
time in mcunths 
<1 
1 
2 
3 
4 
-~ 
8 
total numbe::.~ 
Table 6. :2. 
Table 6.13. 
cell type structure 
I LCS ILBS IRes HBS 
II 
-. ' Cilffusel follicular 
I 
s ?ib 1 83~£ 94r~ 92% i 83~6 I I 
81"'£ I 87;··~ 94?£ 92';b I 89)6 ' , I 
' I 86'fG I 97% 94-J~ 9 2'j£ ' 92;'; 
I 1 oo;S j1 oa;6 92;b 979;, I 
I 1 OCPo I 92 1 ocr;~ 
I 
I 
I I ! I 
'· 
I 1 OCf}o I 
21 1 23 1 6 36 
AoJearance time of local recurrence, i:~ relaTion to 
cell tpe and str-cture. 
/,_uthor Fuks .Present 
Histology 1 973 study 
LCS 35 % 25 d ,, 
LBS 21 ~b 1 9 ,, ,, 
HCS 27 3G 27 d ,, 
HBS 28 o'~ ,, J6 "' ;o 
Diffuse 1 26 ,,· 22 1b 
Follicular I 
,, 
21 ~b 19 ,Ji ,, 
Frequency of I oca I recurrence. 
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so;~ 
7 s;b 
84;; 
·1 oo:;, 
I 
I 
' I
I 
I 
I 
I 
' 
VII. SIDE EFFECTS OF TREATMENT, INFECTIONS. 
1. SIDE EFFECTS. 
Iatrogenic campi I cations are a very important aspect of the treat~ent 
of !'lal ignancy. l\.t present with the increasing avai labi I ity of more potent 
theraoy the incidence of iatrogenic side effects rises correoondingly 
(Heyler and Peck, 1972; P1 oser, 1969). In the case of the present cytostatics 
the therapeutical r-ange is small and therefore each beneficial effect has 
to be paid for ~lith -'1any side effects (Z'Ivaveling, et al., 1973). The same 
applies to irradiation therapy (Kaplan, 1972; Sykes, et al., 1974; Vogel 
and Lunde, 1968; Bull, et al., 1969). 
in the case of radiotherapy the most pr-ominent side effects are 
ulceration of skin and rr-,ucous membranes, bone-riarrow depression, 
oneumonitis, and myelopathy. The main chemotherapeutic agents used in this 
study were 1 l the alkylating agents nitrogen mustard, cyclophosphamide 
and chlorambucil, 2l corticosteroids, 3) procarbazine, and 4) vinca 
alkaloids (see table 6.2). Their most frequent side effects are bone-~arrow 
depression, ~eurotoxicity. haemorrhagic cystitis, diarrhoea and nausea. 
The frequency of side effects occurring in this series is given 1 n Table 7.1 . 
.t\11 therapeutic side effects occurring in individual patients during 
the treatr:ent are included, so that side effects canr.ot be pinpointed to a 
particular treatment at any precise r:oment, but only an avera I I picture 
can be obtained. One rather soecial side effect occurred, the source of 
w~ich could be ascertained: the only case of lungfibrosis was in a patient 
. d . R d . · ·" who rece1ve bleomycin , an th1s as we now know 1s qu1 1e a com~on 
campi I cation of t~is tyoe of drug (Qidhoff anG Schraffordt Koops, 1 972; 
Cragon i, et a I . , ~ 1971). Three other patients on b I eomyc in did not deve I oo 
lungfibrosis. 
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Fourty per cent of patients receiving corticosteroids developed 
campi ications, r-anging from mild Cushings 1 syndrom to fatal gastric 
bleeding. HaeMorrhagic cystitis which is fairly specific for cyclophosphamide 
occurred in 33% of those using it. Neurotoxicity, expressing itself as 
oaraesthesias, pareses, or paralytic ileus occurred solely in oatients 
on vinca-alkaloids; in tact all patients using vinca-alkaloids in the 
present series developed this campi ication at least once. Bone-marrow 
depression may occur as a consequence of cytostatics, and/or irradiation 
(large field with much bone-ffiarrow in it, bone-marrow previously 
compromised by therapy), so no special offender may be singled out. 
In the present study a significant decrease of the leucocytes and 
thro!':1bocytes, to belov1 values of 1.000 and 30.000 respectively, was 
cons·~ d erec to be an i nd i cation of bone-rna rrow deoress ion. 
2. O::ATH DUE TO COHPL I Cfl.T IONS OF THERAPY. 
In twelve oatients treatMent clearly shortened the I ife span of the 
oatient. These twelve patients form 4% of the total number. This frequency 
once More shows the small therapeutic range left for the clinician treating 
lymPhomas. 
3. INFECTIONS. 
The lymohoma is a ideal candidate for infections for many reasons 
(Kiastersky, 1974): 
-abnormal body flora: more resistant and virulent types of bacteria and 
viruses acquired from the hosoital 1 or alrered through selective growth 
under former antibiotic treatment (Feingold, 1970). 
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Side effect % of total 
number o:f patients 
Lung fibrosis } 0,3 Pneumonitis 
Skin ulceration } 8 Mucositis 
Bone marrow 23 
Depression 
Corticosteroid 3.5 Side effect 
Haemorrhagic 1 Cystitis 
Neuritis } 5 Ileus 
Total ~b of L~ 1 
side effects 
Table 7.1. : Side effects of treatment. 
I 
)6 of positive infection of total number, of which 
information about that type of infection exciSts 
...Lnfection type eft ;o of total* 
Bacterial 22 
Herpes 7 3 
Other viral 0 
Opportunistic 3 
Total % 22 
Total, in which a search was made 
for this type of infection. 
Table 7.2. Types of Infections. 
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- comorol'li sed i nf I ammatory response: bone-marrO'"' depression, 
corticosteroids (Levine, et al., 19721, i1'1paired neutrophi I function 
(Rosner, et al., 1970; Lehrer and Cline, 1971), inhibition of macrophage 
function (Cohen, et al., 1974). 
-decreased imrrunoresponse: bone-narrovv depression or the R.~.S.-disease 
itself (Levine, et al., 1972). 
-
1
'broken': anatomic barriers which are no longer infection-resistant: 
invasive diagnostic techniques, catheters (Kass and Scheiderman, 1957>, 
epithelial lesions by radiotherapy (Craig end Farberm, 1953), surgery. 
In the oresent series 22% of the patients had severe infections; 
they are oresented in Table 7.2. Bacterial infections are most prominent, 
only a Minor r61e exists for her~es virus and the more exotic infections 
(fungi, orotozoa, non-her~es virus). It may be expected in the future 
that infection and esoecially by the exot'c pathogens wi II increase 
further, as supoortive measures improve, I ife expectancy lengthens, ana 
trectment becomes more aggressive. Therefore sophisticated bacteri o I ogi ca I 
survei i lance methods and antibiotic treatment wi I I be necessary to get 
the maximum benefit from lymohoma treatMent, without losing the patient 
to fatal infections. 
il =::·ISC\JSSIOI\'. 
There is I ittie systemic information about side effects in the 
iterature, as only a few studies give a ~actual accoJnt. The study of 
::;;osenberg, et al. (1961) oresents a very Viide spectrum of side effects, 
possibly because their series is larger (1,269 ~atientsl and therefore 
contains unfrequent side effects such as radiation ost1tis and I iver 
cirrhosis caused by cytostatic drugs. Fro~ their study too however the 
chief t.,eraoy·-related problems emerge: bone-ma:-row aepression, cor·tico-
steroid effects, skin and Mucosal ulcerations. 
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A few fatal outcomes are mentioned. The incidence of side effects, in the 
study of Rosenberg, et al., seeMs to be lo1ver than in the present study; 
but the sur-vival rate Is lower too. The data of Luce, et al. (1971) using 
combined chemotherapy (cycloohosphamide, vincristine, prednisone) in 
advanced lyrmhoma show a very hign percentage of undesirable side effects: 
bone-marrow depression 88 % (severe 9 %. fatal 1 %1, neuropathy 48 % 
(in 13% requiring complete cessation of therapy}, steroid effects 29 %, 
severe infections 4% and fatal toxicity in 4 patients out of a total of 
262 patients. These authors state that in order to be succesful any 
chemotherapeutic regime must have an '~intrinsic 11 high percerrtage of 
toxicity. The study of Stein, et al. (1974) based on cyci leal courses witG 
cyclophosphamide, vincristine, procarbazine and prednisone describes toxic 
effects in a I I (!) pat i errts. 
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VIII. Ff\,CTORS INFLUENCir'>lG PROGNOSIS. 
1 . I :'HRODUCT! ON. 
Survival is He fact of most interest to both patient and physician. 
By carefully altering certain treatment Modalities, and studying their 
effect on survival results the physician may improve his treatment rnethcds. 
The ideal for a survival study is a very large number of patients, all 
entering the study simultaneously. The study is concluded 't~hen all patients 
have died. Then a reel survival curve can be made, after subtracting those 
~atients who did not die of the disease under study. In practice this 
idea I cannot be otta i ned. 
In this tyoe of stucy it is iMpossible to gather complete data on ali 
patients, because they enter the study at different times; there is 
considerable var:ation in Curation of follm,r-u,J; the number of ent1~ies oer-
year var-ies; a~a it is also possible that in So!Yle oatients the diseas2 has 
not run its f~l I course at the conclusion of the study 
~or- this reoson Three of five-year survival rs-t·es are often used; 
sometimes they are even oresented as 1'cure rate''. The ter-m cur-e rate is 
better- avoided, because many patients die of the disease I ater. A better 
rnethoc to mak.e the rncxir:1o! use (Cutier and Eberer, 1958) of all available 
data is the ef".Dioyment of actuarial I ife-table methods. The sur'Jivc.l ir, 
I ife-table methods Is given as an estimate of the survival chance. It is 
exoressed as survival percentage per year, or as the percentage of the 
total number of oatients, who survive a specified number of years after 
the initial diagnosis or tr-eatment. 
- 66 -
2. STATISTiCAl. ~-~ETHODS. 
in this study the actuarial I ife-table method of Kaplan and 
Meier (1958) was used to analyze the decrease in the number of patients 
during the time of study. Kaplan's method considers the number of patients, 
who enter an observation period (in this s~udy one whole year), and 
compares this with the nu~ber of survivors at the end of that period. 
The survival chance for a period is defined as the quotient of the 
number of surviving/entering oatients in that particular period. 
The chance of survival for a specified number of years is the cumulative 
product of all separate survival chances of the previous years. Any 
patient, v1ho leaves the study during a certain observation period for 
reasons not related to the disease, is not entered in the corrpu"i"ations 
for· '7hat period. 'i'/ith this rPet-hod patients are studied as long as their 
fcllo·~1-up permits; \~hen their foll01·1-up ends, it is not cutorr,aticelly 
assu~ed that they have died of the disease, as is done in simple sur~lva, 
c0rves. The number of patients under consideration decr·eases more 
~uickly, as the survival beco1nes ~anger. ~herefore the standard error in 
the '1 1ast'1 SJrvival years increases, and i~ is hazardous to in~erpret 
survival oercent~ges computed from grouos which contair1 less than five 
ot- ever: ten pctienh. Jl.ll survival tables in this chcpter indicate 
whe~ +he ~emaining number of patients becomes too low. The survival 
line is solid as long as the total number of Datients e:..;ceeds ten; 
it is broken when the number of patients I ies between ten and five. 
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3. SEPAR.'~.TE SURV:VAL FACTORS. 
3.1. lntrodLction. 
r~uch has been written about the influence on survival of eel I type, 
strucl·ure, stage, sex, constitutional sym_~toms, age, bone-rmr-rov< invasion, 
extranoda I start, presence of ""acrop'nages, and of course the type of 
treatment. Most authors have constructed for alI these factors a 
regr·ession co§fficient against survival, i.e. a measure of prognostic 
value, has been constructed, expressed as a three or five year survivai 
rate or more recently as an actuarial survival chance percentage. 
Instead of using multiple regression analysis of survival factors it 
is also possible as done by Jones, et al. (1973) to compare the survival 
character·istics of multi-dimensional categor·ies, e.g. cell type x 
structure x stage x presence of constitutional symptoms. A disadvantage 
of this method is the intense fragmentation of the case materia I, 
which may result in groups, l'lhich are to srr.all for statistical evaluation. 
Also these subgroups, which are compared in their survival rates, may 
differ v1idely in other characteristics, and comparison of their survival 
rates can produce erroneous results. Categorisations of this kind wi II not 
be made in this study but the influence of alI factors together is 
considered in a multiple regression analysis. 
In this chapter the prognostic value of the above factors wi II be 
considered to select the most important for a multiple regression 
analysis in the next chapter. 
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3.2. Clinical stage. 
The influence of the clinical stage according to Ann Arbor on survival 
is depicted in Fig. 8.1. l"t is evident that the prognosis worsens as the 
clinical stage rises. This is in agreement with the results of Peckham 
(1974), Jones, et al. (1974), Lee, et al. (1973) and Fayos, et al. (1974). 
Fig. 8. I. 
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Clinical stage and survival. 
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3.3. Cell type. 
Fig. 8.2. The smaller lymphocytic type (L.C.S.J has the best prognosis, 
the smaller histiocytic type (H.C.S. J the worst. The larger variants of both 
cell types (L.B.S., H.B.S.J show about the same survival. Similar conclusions 
are reached by Rappaport (1956) for foil icular cases only, Jones, et al. 
(1973), ;\1onfardini, et al. (1973), and Patchefsky, et al. {1974). 
survival 
chance 
percentage 
100 
• = LCS n = 86 
90 0 = L8S n = 122 
0 = HCS n~ 61 
80 
' 
' 
' 
B = HBS n= 38 
"' 
=FM n= 7 
70 --- _!;:,. note: all lines solid 
when n ::;:.5 
60 
50 
40 
30 
20 
10 
2 4 6 8 lO 
years of survival 
Fig. 8.2. Ce II type and survi va I. 
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3.4, Structure. 
Fig. 8.3. The foil icular type has a better prognosis than the diffuse 
type. This observation has repeatedly been made since the original pub I ication 
by Rappaport, et al. (1956). Patchefsky, et al. (1974) even subdivide the 
foil icular type and note an improved survival rate as the degree of 
nodularity increases. 
survival 
chance 
percentage 
100 
note: all lines solid 
when n :) 5 
90 
80 
70 
60 
50 
40 
30 ~ ... follicular n= 63 
20 -..0-{) diffuse n = 165 
10 
l 2 3 4 5 6 7 8 9 10 
years of survival 
Fig. 8.3. Structure and survival. 
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3.5. The Dresence of macrophages. 
Fig. 8.4. Because macrophages were seen in only 12 %, no finer 
subdivision was made on the basis of the number of macrophages. There is a 
negative correlation between presence of Macrophages and survival. The same 
was found by Oiamandopoulos and Smith ( 1964) and Van Unnik (1973). The 
reason for the presence of macrophages and their function is not clear. 
According to D i amandopou I os they are reactive ce I Is, which ref I ect the 
immaturity of the I ymphoma ce I Is. However in the newer I i ght of the newer 
facets about different tyoes of histiocytic malignant lymphomas (Lancet, 
1974), the entire oroblem may need reconsideration. 
Fig. B. 4. 
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3.6. Bone-marrow invasion. 
Fig. 8.5. There is no clear effect of bone-marrow invasion on 
survival: initially the positives do better than the negatives, but do 
worse in the ultimate survival. Although there are some data about the 
frequency and significance of bone-marrow involvement (Jones, et al ., 
1972; Jones, et al., 1973), only Bloomfield, et al. (1974) give excct 
·InforMation on its prognostic ·~ nf I uence. In their study the bone-marrow 
invasion appears to be a separate negative prognostic factor in patients 
with stage !V. In the present study there does not seem to be much difference 
in sur~vival figures in stage IV, whether the bone-marrow is positive or 
not. However, the tota I numbers are too sma I I to justify a st:-ong opinion, 
they only oermit an impression. 
50 
45 survival 
chance 
40 percentage 0 
35 
30 
25 
20 
15 
10 
5 -
2 4 6 8 
o n=l8positive 
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* = n < 5 
10 
years of survival 
Fig. 8.5. :Bone-marrow invasion and SL.rvival. 
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all 
ST. IV 
3.7. ConstiTutional symotoms. 
fig. 8.6. There is a strong negative corr·elation betv..,een sur·vival and the 
presence of B-symptoms. In Hodgkin's disease the unfavorable prognostic effect 
of B-symptoms is well knol'.'n (Tubiana, et al., 1971; Kaplan, 1972), but in the 
case of the o·ther ma I i gnant I ymphomas some divergence of opinion exIsts. 
Jones, et al. (1973) state that there is no significant influence but 
Bloomfield, et al. (1974) and Patchefsky, et al. (1974) note a strong 
corre I at ion independent of the c I in i ca I stage. 
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Fig. 8. 6. Constitutional symptoms and survival. 
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18 
Because of Jones' remark that 8-symptoms probably have a bad prognostic 
influence because of their wei I known association with higher cl lnical stages, 
the effect v-.'ithin each clinical stage was computed. It appeared that within 
each stage the unfavor-ab I e i nf I uence of 8-symptoms 1-1as present. The same 
applies within each cytological class. These data are presented in Appendix .J. 
3.8. Sex. 
Fig. 8.7. The wo~en appear to do slightly better. The same trend is seen 
by Lee, et al. (1973), Rosenberg, et al. (1961), Molander and Pack (1963), 
Hansen (1969), and Patd,efsky, et al. (1974); however, in many other studies 
no difference has been noted. 
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Fig. 8. 7. Sex and Stlrvival. 
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3.9. Age. 
Flu. 8.8. There is no important difference between the ~ifterent age 
groups, except for the seventh decade. Only the part of the curves on the 
left-hand side of the asterisks should be considered. Perhaps the seventh 
decade-group shows a shorter survival because of the intrinsically much 
shortened I i fe span of this age group as compared to the younger ones: 
death by other reasons occurs significantly more often. This is in close 
agreement with the authors mentioned in section 3.7 of this chapter and 
also \1/ith Jones, et al. (1973), and Bloomfield {1974). In fact nowhere in 
the literature is the suggestion offered, that age significantly affects 
the survival. 
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Fig. 8.8. :Age and survival. years of survivoi 
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3. 10. Extranodal or nodal ori~ary site. 
Fig. 8.9. The primary site here is only nodal or extranodal 
VIi thout reg i ana I I ymoh nodes. No difference emerges between nod a I and 
extranodal in their influence on survival. 
i= i g. 8. 9. Nodal or extranodal primary site and survival. 
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4. PROGNOSTIC IMPORTANCE OF EACH SEPARATE FACTOR. 
The prognostic imoortance of each separate factor, expressed as the 
simple regression co§fficlent, can be calculated by standard computer 
programs (e.g. I .S.M.-SSP). However the dependent variable, survival, 
cannot be entered as a chance percentage, but has to be in real years or 
months. Therefore Kaplan 1 s method cannot be applied to these calculations. 
It would produce an unrealistic worsening of the survival data. Now every 
patient, in whom the disease cannot yet have run its ful I course, wi I I be 
presumed to have died of the disease at the moment that the follm1-up ends. 
This phenomenon wi I I notably affect the survival data of those patients 
having entered the study in the last few years. In the last two years 76 
patients entered the study ( I ast year 33). The minimal fo I I ow-up to 
closing date is two years and seven months (chapter 2). Another unfavorable 
factor is death from other causes. This has not been eliminated beforehand, 
because the major cause of death is the malignant lymphoma itself. For 
comparison purposes however, the computer program can be modified to 
disregard those 1-.'ho died of other causes. This results in two survival 
curves: total survival and a second survival curve, composed only of those, 
who did not die of other causes (Fig. 8. 10). The correlation coefficients 
are calculated on the basis of survival data in months instead of years. 
This is done, because conversion from months to years, which ls normally 
done by dividing the number of years by twelve and disregarding the 
fractions, will shorten the survival. The single correlations make it 
possible to select the most significant prognostic factors for a multiple 
regression analysis. They also show the relative importance of each 
factor. These corre I at'1 ons are shown in descending order in Tab I e 8. 11. 
- 78 -
100 
90 
80 
70 survival 
chance 
60 
percentage 
n 
50 
40 
30 
20 
10 
2 4 6 
a total n = 314 
6. tumor only n = 281 
note: an lines solid 
when n )5 
8 10 12 
years of survival 
Fig. 8.10. Total survival and tumor survival. 
Prognostic single correlation 
Factor coefficient 
Stage 0. 34 
Const.symptoms 0.31 
Cell-type 0.15 
Structure o. 14 
Age o. 11 
I 
Nacrophages o. 11 
Sex 0.09 
Bone-marrow 0.08 
Nodal/extranodal 0,04 
Table 8.1 1. Prognostic importance of each separate factor. 
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IX. MULTiPLE REGRESSION flJ~fl.USIS OF PROGNOSTIC FACTORS. 
I . I1~TRODUCT I ON. 
Although there are rnany reports on prognostic factors and the effect 
of different methods of treatment on survival, little is known about the 
effect of a II these factors together. In fact it is on I y mentioned in the 
study of Bloomfield, et al. (1974). ~lhen all factors are considered 
simultaneously, it is possible that some factors wi II cancel out the effect 
of others, which in single correlation analysis seemed to be important. 
For instance it may be pass i b I e that constitution a I symptoms occur more 
often in a certain ce! I tyoe, and therefore the i nf I uence on surv iva I of 
this independent variable wi II diminish the importance of the cell type 
and vice versa. The importance of the type of treatment per se wi II 
orobably be smal I, This is caused by the fact, that the type of treatment 
is chosen according to the progression of the disease. Hm._rever, the 
orogression is already exoressed in the other prognostic indices. 
As conventional I ife-table analysis of all prognostic factors 
separately can give a distorted vielv because these factors are often inter-
dependent, it is useful to perform a multi-variate analysis, which 
considers the effect of a I I these Dr-ognost i c factors together- ( Snedecor and 
Cochran, 1972J. This can be achieved by multiple linear regr-ession methods 
as used by stanCard computing programs; i .8.1'·1!.-S.S.P. ',·\'as LJse::J in -n·,is 
study. A prob!e~ is created by the fact that these pr-ogr-sns do ~ct 
di fferer,i·i ate :,et'c.reen dea1h caused by the disease and '\:onsi de r-ed l-o 'ue 
dead'' for- lack of follolt~-up; this 'di II ar-tif;cially depress the survival 
rate. 
\'iultiple I inear regression computer orograms wi II first compute al r 
single correlation coefficients, whic~ in this study are the prognostic 
factors. 
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Subseq'Jently the most iMportant one wi II be singled out, and the relative 
prognostic effect of the second most importan·f one wi I! be calculated in 
viev1 of the known effect of the first. This continues unti! al! possible 
factors have been reviewed. Factors, which are taken into account later. 
will add very litt!e orognostic information, because they are already 
relatively unimportant in single correlation analysis. This makes it 
possible to give nearly as good a prognostic indication with the first 
fev1 prognostic factors. Various combinations of risk factors have to be 
tried in order to find the most useful prediction (Dunn and Clark, 1974). 
This '~las done in accordance 1vith the method of Daniel and V·lood (1971l. 
2. 11 PROGNOSTIC 11 EFFECT OF THE TYPE OF TRFATMENT. 
Although the type of treatment is dependent on some other prognostic 
factors, an atte~pt has been made to evaluate treatment as an independent 
prognostic factor. For the effect of treatment a scale was constructed from 
the data on the effect of the first single treatment. Some data on combined 
treatMents had to be approximated. The total effect {Table 9.1) is therefore 
somewhat unsatisfactory, but may be the best possible one can achieve. The 
single correlation coefficient, or the prognostic effect of the treatment 
type is 0.07. This places the type of treatment nearly at the bottom of the 
list of prognostic factors (see Table 8.11). 
3. RESULTS OF HULTIPLE REGRESSION ANALYSIS, 
Multiple regression analysis identifies clinical stage, constitutional 
symptoms and cell type as tr,e most important prognostic factors: Table 9.2. 
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1 00 Surgery ~ 
90 1''1egavol tage -!- prophylactic f·ields 
70 Megavoltage 
55 Crthovoltage 
40 Surgery + mega + prophylaxis 
40 Surgery + megavo.ltage 
35 
15 
Surgery + orthovolta.ge 
Chemotherapy 
Chemo + surgery 
15 Chemo + irrad, any type 
15 Chemo + irrad 1 anytype + surgery 
0 No treatment 
• Note: These 13 cases treated by surgery alone 
are very selected as they cousist of 
small localized tumors. 
Table 9.1. 11 Prognost i c ef fect 11 of treatment. 
Prognostic Hul tiple regres-
Factor sion coefficient 
Stage 0.28 
Constitutional symptoms 0.18 
Cell type o. 14 
Macrophages 0.09 
Nodal/Extranodal 0.08 
Treatment 0.07 
Age 0-05 
Structure 0.05 
Sex 0.02 
Bone-marrow 0.02 
Table 9.2. ~1u!tiple regression analysis of all prognostic factors. 
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They alone produce 93% of the possible prediction. Addition of 11 presence 
of macrophagesn gives some improvement, as the total prediction force n0\'·.1 
rises to 96%. Age, sex, extranodal involvement, bone-marrovl invasion and 
structure do not influence prognosis significantly. These findings indicate 
a downward shift in importance of structure and a rise of the presence of 
~acrophages, when compared to the single correlation coefficient results as 
shown in the last chapter. Therefore the major part of the prognostic 
message of the structure is probably contained in the three most important 
parameters. In the study of Bloomfield, et al. ( 1974) bone-marrow positivity 
aopears to be very important; this is not so in the present study. The 
total multiple correlation or the prediction value, which can be obtained 
by combining histology, clinical symptoms and bone-marrow as, indicated by 
Bloomfield, is in this study 83 %, which is considerably lower than the 
one in which bone-marrow is replaced by clinical stage: 93 %. This 
discrepancy can have several reasons: different patient population, 
too short follow-up in Bloomfield's study, insufficient bone-marrow sampling 
in the present study. The importance of macrophages has not been noted 
before, probably because not much attention has been focused on this 
phenoMenon. On I y D i amandopou I os and Smith ( 1964) have studied their effect 
in depth; they considered their presence an unfavorable sign. 
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X. PATTER!'JS OF SPRF.;D. 
1 , ~·.'ETI-iODS OF SPREAD. 
Hm1 non-Hodgkinis lymphonas spread has iong been considered as 
unpredictable (Scheer, 1968; Han and Stutz, 1967; Banfi, et ;:,I., 1968), 
and resulted in some therapeutic nihi I ism (Newall, et al., 1968). 
Ho1r1ever the finding of Rosenberg and Kaplan (1966) that Hodgkin's disease is 
potentially curable, since it begins as an unicen7ric focu"- and disseminates 
in an orderly progression via the lymPhatic channels, has caused a review of 
the me~hanism of spread in the other lymphomas. Patterns of spread can be 
studied in two ways: 
a. the first method maps all initially involved sites and notes VJhetner they 
are contiguous. Contiguous lymph node regions are I isted in Table 10.1. 
Thls method requires a routine laparotomy, because quite a few 
IJmpr. r1o.jes may be positive (Veronesi, et al., 1974), 1r1hich seemed 
negative on the basis of lymphography or which are otherwise undetectable 
(e.g. Mesenteric nodes). Verones1 1 s study (1974) shows contiguity of 
lymphatic involvement in 73 %. Moran (1973) who also uses staging 
laparotomy flnds contiguous spread too (notably in lymphosarcoma). The 
same conclusion is reached by Goffinet, et al. (1973). 
b. The sec-::;,nd method starts with the localized involvement only (i.e. stage ll 
ar.d notes where the next manifestation of the disease cccurs. All recent 
studies whi~h start from a single point, show contiguous spread via the 
lymphatic channels (Peters, et al ., 1968; AI-Saleem, et al ., 1970; 
Rosenberg and Kaplan, 1968; Lioton and Burton, 1971; Jones, et al., 1973) 
in about 70 %; distant spread occurs in 30 %. 
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In the ore~ent series the pattern of spread of alI unifocal primary 
sites was studied. Table 10.2 summarizes the results. It appears that the 
supradiaphragmatic lymph nodes (except the mediastinum) show contiguous 
spread, which means either the next lymph node or an adjacent organ, in 64 % 
(80% xl. The diaphragm is passed in 36 %; 69% (78% xl of the spread 
involves lymph nodes. No evaluation was done on the very few stage I 
infradiachragmatic nodal presentations. 
;he localized organ involvements (stage I without regional lymph 
nodes) show a di~ferent behavior. Only 28 % (43 %l show regional spread; 
50 % pass the diaphrdgm, 64 % of the spread is to a lymph node. The 
results of this st~dy also show a very clear tendency towards contiguous 
spread in the case of primary nodal i~volvement. The behavior of the 
primary organ iocal izations is More erra7ic and th~refore unpredictabie. 
This last fact ry1av be creal funcrion of primc1ry organ involvsrnents, or 
it M2Y be caused bv either insufficient staging in the preser,t study or 
the bias which a few abnormal cases may introduce in such a smal I total 
nur:1b~r o·l cases. Hm,:ever t"ne findings oresented he1-e are ore more a~gc.Jme~·,t 
for irradiation therapy, which includes the adjacent ly~phatic regior1. 
/-.!:hough a 1:1al ignant lyrnpl--.ol"a spr·eads via the lyr:.phat!c channels to 
the 11ex~ !ymph node, one exceotion occurs to be nresent: the skiopl11~ of 
the nediastinum. In fact (see below) the mediast :1um of often passed 
s i I enT i y V<her, a stage I becomes a stage I I I. Hcv,rever, th! s is net a rea 1 
exception, because oara-aortic lymph noues are cor.nected direct-ly to ·l·he 
nodes of the left side of the neck (Rouvi~re, 1932). 
x Note: the nun1ber in parentheses includes local rec11rrence. 
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Thus spread from n"'ck lymph nodes to oara-aortic nodes may or- "lay not 
involve the mediastinum and ';Ti II be contiguous. This has an important 
therapeutic consequence. If tr.e mediastinum is skipped very often during 
soread, it· is not useful to include it in routine oroohylactic regional 
irradiation and thus not to impair the hematopoietic activities of a 
considerable part of the bon8-marrow, ~ut better to remain watchful and 
perform regular tomograohic controls of this ''regiorr at risk'" (Van der 
1tlerf-Hessing, '968). In the completely staged cases of 1/eronesi, et al. 
( 1974) mediastinal skipoing occurred in 97 %. The study of Jones, eta:. 
(1973) sho•r~s 72 %, th<lt of Van Cer ·~lerf-~.,lessirrg (i969), sh01~s 94%, and that 
::-!f r'art and Stutzrr-,an (1967) sho•iiS 100% mediastinal s~:oping. 
To stuoy the frequGncy of this skipp:ng p~:enomenon mediastir,ol 
tur"or ir';olve,....ent as seen on ><-rays ·,·las investigated ir1 the follov1ing 
(only nodal) ccses: 
1. first presentation stage I! I. 
2. fi(st relaj::se cor~respo;1ding to stage Ill, but at f'rst presentation 
stage i cr II ·,, .. :thout mediastinal involvement. 
3. second r-e: apse cor-r-esJond i ng to stage I i I, bet ct first r-eI apse 
cor~esoondirrg to stage I or · i without r1ediastinal involvement. 
The r-esults ar-e given in Table 10.3. r .. ~ediastinal skipping occurs ;n 71 %. 
The lyrr,phocytic types r--av"" a higher· tendency to involve. rhe rr.ed:.:ostinur· 
,·1her: pi:issirrg to the otr.er side of the rjiaoh1-ogm: 33% ver,us 16% for· the; 
histiocytic types. -here is no difference bstween diffuse and fcl I icular 
sk.Jpir'g, especially in -!"he histiocytic tyoeo>. Probably the percentage ct· 
pr-ocedures had been used in e~ch C3Se. However, ev~n thsse data urge 
restraint vhen considf:rin~J ~"':ediastinal irradiation Cl'· a oro~hylact:c 
regtonal treatment. 
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Pr.imary site 
Cervical or 
supraclavicular 
Mediastinal 
Secondary involvement 
- Supraclavicular 
- Ipsil ateral axillary 
- Hediastinal 
- Contralate ral neck, supraclavi 
cular 
- Cervical 
- Supraclavicular 
- Para aortic 
- Axillary 
Jtxillary Ipsilateral cervical, supraclavicular 
- Medias tina 1 
Inguinal - Ipsilateral iliacl femoral 
- Para aortic 
Para aortic - Mediastinal 
I - Iliac - Left cervical 
Table 10.1.: Contiguous lymph nodes (after i"lolander and Lacayo, 1970). 
Supradiaphrag-
rna tic nodes,ex Organs 
cept medias-
tinum 
Contiguous 64 % * 80 ,: 28 % * 43 I' 
To any lymphnode 69 " I' * 78 ;;, 64 " I' 
Via diaphragm 36 % 50 " I' 
Total number 44 
~~ote: The numbers preceded with an asterik include 
local recurrence 
Table 10.2. Spread patterns froM stage I. 
,: 
I' 
I Mediastinal I LCS HBS HCS HBS FM Tot Diff 1Foll 
fSkipped I 1 1 1 J I 5 0 2 31 1 2 I 1 1 
Not-skipped I 7 5 0 1 0 1 J 4 4 
Total i 18 1 8 5 1 2 44 16 1 5 
Table 10.3, Occurrence of mediastinal skipping. 
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Tot~ 
23 
I 8 
I 
I 
31 I 
I 
Xi . LElJ<Ei··,11 C DE\fE: L0°~,..1ENT, SOH':: LCC.J\L I ZED CHGf\JJ I ~J\/Cl. \/EHE!\ITS. 
i. I NTCl:ODUCT I 0>-J TO L_EUKI:::H I C DEVE L.OPr~ENT. 
The occurrence of a leukemic phase in lyr:ohosarcoMa is wei I known 
(r-ilolander and Pock, 1963) and relaTively frequent (Posenberg, et al., 1961; 
lbbot and 't.lhitele·.•}, 1966); in reticulum ce! I SdrcoMa this is rarer 
(Loewenbaum, et al ., 1971) and here the cytological type of the circulating 
cell is different (Schnitzer and :<ass, 1973) from tr:at of lymphocytic "lalignanl-
lymphoma. 
The ly~ohosarcona eel I leuke~ia (L.S.C.L. l has now gained acceotance 
as a separate entity to chronic lymphatic leukemia, and is probably a 
dissemination into the oeripherai blood of r-,al ignant lyr:ohocytic lymphoma 
cells (Sch'.·.•artz, et al., 1965). The differentiation is made on tne basis 
of the total nurr·ber, and in particular the cytological asoects (Dick, et al., 
1972) of the circ~lating lymphocytes, as there is i ittle significant 
difference in clinical oresentation (Zacharski and Linman, 1969l. The 
invasion of the bone-marrow is not decisive for the diag~osis (Die~. et al ., 
1974; Ryrol in, et al ,, 1974), The pathological Jeripheral ly:Ylphocytes 
consistently disolay atypical features which distinguish them fro~ normal 
lyr-;ohocytes: there is considerable cytological pleomorphism, and often 
nuclear cleft!ng and folding. ryperchrol'1atic nuclei, a large cell-diameter, 
the oresence of one and rarely t··.vo or More nucleoli are seen. Leuke~ic 
development is most ofte;~ described in diffuse lymphoma (Sc'lnitzer and Kass, 
1973; Stenfert Kroese, et al., 1973). The prognosis of those L.S.C,·~. arisen 
from fol I icular lyrrphomas aooears to be better than those arising from diffuse 
lymphomas although the original lymphomas very often convert to a diffuse tyoe 
finally (Schnitzer and Kass, 1973). Hov1ever the survival frorr- the onset of 
leukemia is very short, varying from 9 months in the diffuse lyMphoma to 18 
months in the fo I 11 cuI ar i ymphoma. 
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Leukemic development occurs r~ore often in children (Schey, et al., 1973) 
than in adults. 
Occurrence of leukemic development in reticulum eel I sarcoma is rarer-
although Hath§, et ai. (1970) disagree at this point. The peripheral leukemic 
cells may remain a rrore primitive histiocytic cell or closely resemble the 
monocyte as seen in Schi I I ing 1 s leukemia (Butler, 1970). Once the leukemic 
phase has begun the prognosis is measured in a very few months (Zeffren 
and Ultmann, 1960; Loewenbraun, et ai ., 1971; Schnitzer and Kass, 1973). 
There are also sor~e case reoorts (Gunz, et al., 1973; Pal, et al., 1973) of 
malignant lymphoma with later (therapy induced?) ~yeloid leukemia. 
2. LEUKP .. ~ i A DEVE LOPHE.'H IN THE PRESENT STUDY. 
In the present study leukemic development was also present in a number 
of cases. To be considered as such, in the differential count of the 
peripheral (Hay-GrUnwald-Giemsa stained) blood film, at least 25% of the 
cells had to be pathological. P,t first Jresentation 2.5% of the oatients 
were in the leukemic phase, at first relapse 4.2 %, and at the second relaose 
2 %. The avera I I percentage is 5. 5 - on I y one of these cases being coexistent 
VJith a reticulum cell sar-coma: Table 11.1. The structure of the original 
lymphoma was diffuse in twelve out of fourteen cases of L.C.S.L., in which 
the structur-e is known for cer-tain; i.e. 89 %. The age distr-ibution is 
given in Fig. 11 .2. Leukemic development, when not pr-esent at the first 
presentation, always occurred within one year; the mean appearance time for 
those derived from diffuse lymphoma is 3.8 months, for the others it is 
4.8 months. This is another confirmation of the diffuse lymphoma. Survival 
after the diagnosis of the leukemic develooment (Table 11.3) is very short. 
One very interesting case of leukemia and lymphoma was present. This patient 
had a diffuse histioblastosarcoma (Rappaport: 11 diffuse undiffer-entiated 
malignant lymohoma 11 ) of the nasooharynx. It was tr:eated by orthovoltage. 
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At start First relapse Second relapse Total 
Lymphatic lymphoma 7 7 2 16 
Histiocytic lymphoma II 1 11 0 0 11 1 II 
Total n 314 180 94 -
Table 11.1. Leukemic development. 
0 at start 
~ at first relapse 
number 
10 ~ at second relapse 
9 
8 
7 
6 
5 
4 
3 
2 ~ I 1 0 ~ 0 
0 2 3 4 5 6 7 8 9 age in decades 
Fig. 11 .2. Age distribution of oatients showing leukemic development. 
Years : 0 1 2 J 4 
At start n ~ 7 2 1 1 0 
1 st Relapse n ~ 7* 1 1 1 
2 nd Relapse n ~ 2 0 
* One case, a histioblastosarcoma 
discussed separately in the text 
Table 11.3. Survival since leukemic development. 
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5 6 
1 0 
At the time of presentation there was also a chronic lymphatic leukemia 
(152.000 leukocytes with 98% of smal I mature lymphocytes). The leukemia had 
only been treated elsewhere with splenic irradiations. The patient I ived for 
12! years after the diagnosis, and died of myocardial infarction at the age 
of 82 years. Three of his close relatives died of (non-skin) malignancies, 
so there was probably some genetic(?) predisposition in this family. 
In conclusion: the frequency, age distribution, cell type and structure 
of the original lymphoma, appearance time, and prognosis all closely agree 
with other studies (Stenfert Kroese, et al., 1973; Schnitzer and Kass, 1973). 
The occurrence of two different ma I i gnant I ymphoprol i ferati ve diseases is 
rare, but not unknown (Kim and Dorfman, 1974). There are, however, some case 
reports (Gunz, et al., 1973; Pal, et al., 1973) of lymphosarcoma coexistent 
with later (therapy-induced?) myeloid leukemia. 
3. SOME LOCALIZED ORGAN INVOLVEMENTS. 
It has often been stated that some extranodal primary sites, whether 
accompanied by regional lymph nodes or not, have a better prognosis than 
others with a comparable stage. This would appear to be especially so in the 
case of gastrointestinal lymphomas (Sherrick, et al., 1965; Peters, et al., 
1968). To evaluate these statements a comparison was made between the 
prognosis of some primary extranodal lymphomas (stage I or II), which are 
especially mentioned in these reports, and the rest of stage I or II. 
4. UPPER RESPIRATORY TRACT, EXCEPT WALDEYER'S RING. 
Involvement in stage I or II is 8% (13 patients: 2 L.C.S., 4 L.B.S., 
4 H.C.S. and 3 H. B.S.). The survival rate seems worse than average for these 
stages. However this can only be an impression, as the total number is smal I. 
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There are a few studies which give comprehensive survival curves for 
involvement of the upper respiratory tract (Enr:uyer 1 et al., 1963; Vander 
Wert-Messing, 1968), but it is not possible to separate those cases with 
involvement of \r.Jaldeyer 1 s ring from the others. N1oreover the staging is r.ot 
comparab I e. 
5. GP,STROii\JTESTINAL TRACT. 
5.1. Stomach. 
Wuch has been written about primary lymphoma of the stomach. This tumor 
is frequent arnong the orimary sarcomas of the stor~ach. Its symotoms are 
non-specific, being those of any gastric "',al ignancy U~olander and Pack, 
1963; Zwavel ing, et at., 1969}. A ~reoperatlve diagnosis has oecome possiole 
tlecause of the avai labi I ity of fiber-endoscope biopsy techniques. In a study 
carried out at the Mayo Clinic (Stobbe, et at., 1966) localized lyMphomas 
formed 21% of all gastric malignancies. Surgical treatment with subsequent 
results in 5 and 10 year survival oercentages of respectively 65 and 50. 
,A, study of Zwavel ing, et al. (1969) !'lentions a 5 year survival of approximately 
50% in case of resectable lymphomas. In the oresent series 11 primary gastric 
lymphomas occur (3 L.C.S., 7 L.B.S. and 1 H.C.S.J, representing 6% of at I 
stage I or I I I yrnphomas. The d i agnes is was never made preoperative I y. The 
5 year, ',.;ith the same methods of treatment as Zwavel ing, survival in this 
small series is high: 73%: Fig. 11.4. 
5.2. Small intestine. 
Ma I i gnant I ymphoma of the sma I I intestine a I so 1 s diagnosed most often 
during surgery. Foremostly it occurs in the terminal i leurn (Wheelock, et at., 
1963). 
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100 
60 
50 
40 
30 
0 
Fig. II .4. 
survival 
chance 
percentage 
n "' 11 
n"' 161 
etc. 
......_.. ST 1/11 stomach positive 
lil---i!ll ST 1/11 stomach negative 
[
- o>lO ] 
---- 10>n>5 
0 2 3 4 5 6 7 8 years of survival 
Survival of localized malignant lymphoma of the stomach. 
The symptoms are non-specific; malabsorption (AI-Saleem and AI-Bahrani, 1973; 
Eidelman, et al., 1966), loss of weight, malaise, secondary anemia or 
intussusception (Marcuse and Puraly Stout, 1950). Sometimes the barium meal 
gives a diagnostic clue (Friedel I, 1954; Messinger, et al., 1973). Tumor 
extension is usually longitudinally along the mucosa (Molander and Pack, 
1963), and this may give a different picture from that normally seen with 
an adenocarcinoma. In the latter case obstruction is prominent; dilatation of 
the lumen, polyposis and th:Ckening of the rugae however, point to malignant 
lymphoma. 
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in the present series 4% (6 patients: 2 L.C.S. and 4 L.B.S.l had 
localized intestinal involvement. In no case the diagnosis was made before 
surgery. Treatment by surgery and intensive irradiation has resulted In a 
better surviva I percentage than that of the other cases ~lith stage I and II, 
namely: 67 versus 42 %. 
5.3. Colon. 
Primary Involvement occurs in 5 patients (2 L.C.S. and 3 L.B.S. J 
reoresenting 3% of all stage I and II patients. The result of treatment 
by surgery and subseauent radiotherapy was unimpressive: 3 patients died 
within one year, all within three years. 
5.4. Conclusicr on gastrointestinal involvement. 
Gastrointestinal prir"rary involvement occurs quite often, stomach and 
sMall intestine, being favoured sites. In nearly all cases the exact 
diagnosis is made after surgery since the symptoms are those of any 
gastrointestinal malignancy. Except for gastric lymphomas prognosis is 
comparable with other localized forms (stages I and I I together). 
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XII. SUI'IMARY AND CONCLUSIONS. 
CHAPTER 1 gives a short introduction. 
A comparison is made beh1een Hodgkin's disease and the other lymphomas. 
Some questions are posed to be solved by the techniques which have proved 
themselves to be so succesful in the case of Hodgkin's disease. 
CHlWTER 2 discusses the material and methods. 
The 314 patients are from the Rotterdam Radiotherapy Institute. 
They represent one-third of alI patients with a malignant non-Hodgkin 1 s 
lymphoma in the years 1950 to 1971. The original histology slides of each 
patient have been reviewed and reclassified according to Rappaport. The 
clinical and therapeutical data (Appendix B) about the first three attacks 
have been put on computer punchcards. The clinical staging has been done in 
accordance with the criteria of the Ann Arbor conference. The closing date 
st 
of the study was 1 September, 1973; this gives a minimum follow-up of at 
least two years and seven months. Cross-tables in maximally seven dimensions 
have been compiled by means of specially designed computer programs 
{Appendix C) using an I .B.M. 1130 computer. 
CHAPTER 3 discusses the histology. 
After a short review which gives an out I ine of the concepts lympho 
sarcoma and reticulum eel I sarcoma, the classification of Rappaport is 
discussed, who differentiates between Two structural possibi I ities: diffuse 
and nodular (or foil icular). There are two different cell types: lymphocyte 
and histiocyte, which both may show different degrees of differentiation. 
This results in four cytological types: well differentiated lymphocytic, 
poorly differentiated lymphocytic, histiocytic and histioblastic or 
undifferentiated. There are also cytologically mixed forms. 
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In the present study Rappaport's cytological view is slightly modified. 
The equivalents are: 
L.C.S. : lymphocytosarcoma 
lymphoma. 
L.B.S. lymphoblastosarcoma 
lymphoma. 
histiocytosarcoma 
Rappaport's wei I differentiated lymphocytic 
Rappaport's poorly differentiated lymphocytic 
Rappaport's histiocytic lymphoma. H.C.S. 
H. B.S. histioblastosarcoma ~ Rappaport's undifferentiated lymphoma. 
Diffuse mixed has been considered as diffuse lymphocytic; foil icular mixed 
as a separate category. 
A problem, caused by the retrospective nature of this study, is a 
probable underrepresentation of the foil icular structural variant; this is 
caused by the fact that the histological review has been done without the 
special reticulin stains which are sometimes necessary for the decision on 
the exact structure. 
The current views on structure and function of the normal lymph node 
are discussed. These are on some points in contrast with the ideas of 
Rappaport. The lymph node contains dendritic macrophages, normal macrophages, 
T-lymphocytes and 8-lymphocyte-derivates. From the B-lymphocyte the larger 
immunoblasts are formed in the foil icle centre after antigenic stimulus. 
They form vi a an intermediate stage of ''c I eaved ce I 111 ; I ater they may 
develop into plasma eel Is. 
Little remains of the former group of reticulum eel I sarcoma: only a 
small group of phagocytosing histiocytes. The biggest part of the group 
consists of tumors formed by transforming lymphocytes, dendritic reticulum 
cells, poorly differentiated fibroblasts and lymph node metastases of 
anaplastic carcinomas. 
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These views originate from studies 1~ith immunological cell-markers, 
enzymo cyto hemistry, electron-microscopic and especially fran careful 
light-microscopic observation of all stages of the transfor'"'ling lymphocyte" 
A better and more physiologic classification is sti II hotly debated. 
The foil icular lymphor1as probably originate from 8-lymphocytes in the 
germinal centre, or from their derivates: the cleaved and non-cleaved 
foil icle centre cells. The diffuse lymphomas may arise from B- or T-lympho-
cytes; there is as yet no common opinion about this. The real reticulum cell 
sarcomas, originating from the phagocytosing histiocyte, are rare. 
The pathogenetic mechanisms also are sti II partly unclear. Most probable 
is a combination of viral infection and immuno-genetic predestination. 
This wi I I start the malignant degeneration, e.g. by blocking further normal 
development of the lymphocyte or derepression of certain stages of development. 
Immune mechanisms are very important as can be deducted from the very high 
frequency of malignant lymphomas in patients 1-1ho are treated by immuno 
suppressive drugs. 
CHA.PTER 4 reviev,1s the histological and clinical data; they are coMpared 
with the I iterature. 
The most important presenting complaints are (painless) lymph node 
enlargement, ENT problems, and abdominal complaints; skin abnormalities are 
relatively frequent too. In 25% there are constitutional symptoms. 
The tumor localization at presentation is nodal in 85 %, and exclusively 
nod a I in 42 %. Of these I ymph nodes the nodes of the neck are the most 
important; after these in descending order of frequency: axillary, mediastinal, 
inguinal, splenic and abdominal. In primary extranodal presentations, v1hich 
are much less frequent, the frequency order is: skin, gastrointestinal, 
respiratory tract, bone-marrow. 
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The localizations in stage I are discussed separately because it is 
impossible to determine the origin of the lyr::phoma in an overail reviev1 of 21 i 
presenting sites. The localizations in stage I do give, per definition, the 
orimary origin of the tur10r. !n stage I the lymph nodes elsa predominate-
especi a I I y those of the neck; a I so there is the same frequency order of organ 
localizations. 
The distribution of the clinical stages shows an unexplained dip in 
stage I I I. 
The histology is divided into cell type and structure. ~·~en ar:d women 
are evenly distributed over the eel I tyoes; but in the diffusely structured 
category men predorr:inate. The frequency of cell types is: '~'LD.Ly.:..y. (L.C.S.) 
27 %, P.D.Ly.Ly. (L.B.S.J 39 %, ~.Ly. (H.C.S.J 19 %, U.Ly. (H.B.S.J 12%. 
foil icular mixed (F.I'·'I.l 2 %. The VLD.Ly.Ly. has a toll icular structure in 
40 %, the others have a predominantly diffuse structure (83-93 %J. 
\.·lacrophages are present in 10 % of a II cases. 
Five per cent of all ;)atients develoo a second neoplasm after the 
diagnosis of the l'lalignant lymphoma; it occurs esoecially in patients '•\'ith 
I ymphocyt i c I ymphomas. Ha If of these second neap I asl"',s are I oca I i zed in the 
sKin. it is unclear whether malignant lymphoma favors a higher incidence 
of other tu~ors. Bone-marrow aspiration has been carried out in 38 %; the 
result of these asoirations was positive in 21 %. Diffuse lymphomas show a 
higher incidence of bone-marrow infiltration. According to the current 
opinion both the i ntens it i vi ty and the me tho~ of samp I i ng cou I d be improved, 
There is no difference between the sexes regarding the frequency of 
malignant lymphoma. The age distribution of both sexes shows a predominance 
of the I ater decades; however the average age of v10men is somewhat h 1 gher 
(55 versus 52 years). 
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CHAPTER 5 discusses the relation between cell type, structure, primary 
localization, constitutional symptoms and age. 
The fol I icular structure is infrequent (approximately 10 %l except for 
W.D.Ly.Ly. or L.C.S. (40 %l. In each stage the percentage of foil icular 
lymphomas is nearly the same. This implicates that the follicular lymphoma 
is just as aggressive as the diffuse type, because otherwise the diffuse 
type would have predominated in the higher stages. The low frequency of 
stage Ill is interesting; it occurs with all cell types and is independent 
of the structure. It seems that all lymphomas skip this stage and disseminate 
quickly - probably hematogenously. This is clearly different from Hodgkin 1 s 
c!isease. 
Although the average age at presentation is the same for all cell types, 
the histiocytic types seldom occur below the age of 20. The age distribution 
curve resembles those of most solid tumors, and does not have the bir::odal 
form of Hodgkints disease. Within each age group the distribution of clinical 
stages is nearly the same. 
No eel I type shows a higher tendency for extranodal primary origin than 
the others; the frequency for all is approximately 13 %. 
ConstiTutional symptoms increase with the clinical stage. The percentage 
is the same withIn each ce I I type. Therefore the patients wl th canst i tut ion a I 
sympToms are concentraTed in the higher sTages in each ce I I type. 
CHAPTER 6 discusses the treatment forms and results. 
Locoregional lymphomas, sTage I and II ~lith or withouT consTituTional 
symptoms, have been irradiated; sometimes surgery has been employed too. 
More disseminated lymphomas have been treated by chemotherapy; sometimes 
localized radiotherapy or surgery has been used as well. 
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In the earlier years radiotherapy has predominantly consisted of 
orthovo I tage; I ater meg avo I tage has been used. In some megavo I tage 
irradiations the surrounding areas or contiguous lymph node stations have 
been irradiated electively. Surgery has been used in 10% of alI treatments 
but mostly for palliation; curative surgery 1vithout any other treatment 
has been used in only 3! %. Chemotherapy was mainly given as a single agent: 
corticosteroids, alkylating agents, procarbazine, vinca-alkaioids. 
Death by tumor occurs in 66 % of a I I patients - minima I fo I I ov .. '-UP 
almost 3 years. The 3 and 5 year survival are 37 and 25% respectively. 
The frequency of complete remission is highest after the first treatment, 
which has to be olanned with maximum curabi I ity potential. 
The frequency of complete remission rises l'lith the increase in 
intensity of the radiotherapy, expressed in dosage and radiation field: 
orthovoltage 50 %, megavoltage 65 %, Megavoltage with prophylactic irradiation 
74%. It should be noted that the orthovoltage-irradiation has been given in 
the earlier years, v1hen clinical staging was not as sophisticated as n0'8adays. 
Surgery has been employed as single treatment in some very selected 
cases; such as excision of a small localized tumor. In this case the success 
rate is high: 83% complete remissions. 
Chemotherapy has a success rate of only 18 % complete remissions. 
A complete remission is obtained in 50 to 60% by the first treatment 
in all cell types; the upper limit is given by P.D.Ly.Ly. {L.B.S.) and U.Ly. 
(H.B.S.l. The duration of the complete remission however is clearly shorter 
in the hi sti ocyti c ce I I types and the diffuse I y structured ones. Therefore 
the quality of the first complete remission (expressed as the product of 
frequency and duration) is poorest in the case of diffuse histiocytic lympho-
mas. There is no clear relation between the duration of the first and the 
second complete remission. 
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Local recurrences arise nore often and faster i:, the case of hisl·iocytic 
iymphon<:~s .. A.Ithough the local recurrence occur·s more ~-acidly in the Ciffuse 
structures, the ultimate nurr~ber is the saMe as in the foil icuiar structures. 
The relation between local recurrence and irradiation data has not been 
studied. 
CHAPTi.:R 7 discusses the detrir:ential side effects of the treatment, a;,d the 
infections. 
Serious side effects of treatment are almost unavoidable because the 
treatment has to be at least as aggressive as the tumor. In the present 
study 41% of the oatients have shovm serious side effects. ~<ost frequent 
are bone-marrovv deor-ession, ulceration, neuritis and cor-i·ic:osteroid effects. 
Neur-itis has occur-red in alI paTients, using vinca-alkaloids. Corticosteroid 
effects nave occurred in 40% of its users, and haenorrhagic cystitis in 
33% of the cycloohosphamide users. 
In 12 patients, i.e. 4% of tile total number, the treatment has mar:c;ecly 
shor-tened the I i fe-span. 
Infections occur very easily in this type of oatient; ther-e are nany 
causes for this: lowered imMunity a~d inflammation defence, abnor-rrol body 
flora, broken anatorr.ic barriers. Twenty-two per ce:>t of a! I patients hav0 ha,j 
an infection, most often a bacter-ial infection; herpes zoster and more exotic 
infections are unimportant. This may be caused by the ~act that during the 
present study the diagnosis of tl-1ese last hw vJas sti II rather difficult. 
CHAPTCR 8 discusses the relative ·mportance of prognostic factors. 
Survivai is exoressed as survival chance per year in accordance with the 
method of Kaplan and Meier. 
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This actuarial method makes it possible to get maximum inforr'lation from 
incomplete data, which are per se produced by a study with this set-up. 
This is caused by the fact that the follow-up is different, and may be too 
short in some cases for the disease to have run its full course. A number of 
so-ca lied prognostic factors are derived from the I iterature. Each factor 
has been correlated with the survival rate; the correlation coefficient is 
also calculated. 
Clinical stage appears to be the most important factor (correlation 
coefficient 0.34), closely followed by the presence of systemic symptoms 
(0.31 ). Cel I tyee and structure follow at some distance (0.15 and 0.14 
respectively). The prognostic order of the cell types is; F.M., L.C.S., 
L.B.S., H.B.S. and H.C.S. The diffuse usely structured lymphomas have a worse 
prognosis than the fol I icular ones. 
Age at presentation (0.11), presence of macrophages (0.11), sex (0.09), 
bone-marrow invasion (0.08) and nodal start (0.04l alI have a low prognostic 
influence. 
CHAPTER 9 discusses the interdependence of the prognostic factors. 
Since some prognostics are closely related with other prognostic factors, 
and sometimes even derived from them, it is useful when considering the total 
prognosis for one particular patient to compute the effect of all factors 
together; after this calculation the most important factors may be singled 
out for clinical use. 
It appears that consideration of a) clinical stage, b) presence of 
systemic symptoms, and c) cell type, provide 93% of the total prognosis. 
If the presence of macrophages is taken in account as well, the prediction 
rises to 96 %. Structure, age, sex, bone-marrow invasion, and extranodal 
start all are relatively unimportant. 
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CHAPTER 10 discusses the methods of spread. 
StartIng from stage I at first presentation the way of spread I ead i ng 
to the first relapse has been studied. 
In the case of the primary nodal presentation, there is a very high 
tendency to orderly spread along the lymphatic channels. In contrast, the 
primary organ localizations definitely do not show this trait. This can be 
an argument to irradiate the adjacent lymph nodes, when the primary 
presentation is nodal. 
The mediastinum is skipped in a very high percentage, when the tumor 
spread passes the diaphragm. The lymphocytic types have a slightly higher 
tendency to attack the mediastinum than the histiocytic ones; structure makes 
no difference. Prophylactic mediastinal irradiation is not useful, because 
of the tendency for mediastinal skipping during spread. 
CHAPTER 11 discusses leukemic development and some primary organ 
localizations. 
The lymphosarcoma cell leukemia is differentiated from chronic lymphatic 
leukemia on cytological grounds. In the present study 16 patients do have or 
develop leukemic development of their lymphocytic lymphoma; in 90 % the 
original lymphoma has a diffuse structure. The appearancetime of the leukemic 
development is always less than one year. The survival after the leukemic 
dissemination is about 4 months - somewhat longer when the parent lymphoma 
has a fall icular structure. 
One patient with a stage I histioblastosarcoma was known years before 
this diagnosis to have a quiet chronic lymphatic leukemia; he died 12 years 
later of a myocardial infarction. Probably the concurrence of two lymphatic 
malignancies is merely a coincidence. 
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It has been said that some orimary organ localizations have a more 
favorable prognosis. In this series the survival of some of these so-cal led 
special localized cases is comoared ·vlith the survival cf all stages I ::;nd II, 
i.e. all localized lymphomas together. 
The survival of primary lymphomas of the skin and of the Ei'H region 
(minus Waldeyer 1 s ring) is not longer than average. It may be even somewhat 
shorter; however the smal I total numbers do not oermlt an exact conclusion. 
Of all primary gastrointestinal lymphomas- of v1hich the diagnosis v1as 
incidentlcally neve< made o<eoperatively- those originating from the small 
intestine and from the colon do have a slightly better, respectively '-'.'orse 
prognosis than average. Hmi8ver, because here too the tota I number is sma I I, 
this remark is only anecdotal. 
The primary gastric lymphomas, eleven in number, have been treated by 
surgery and extensive irradiation. Here the survival rate is clearly higher 
than average for their stage: more than 70% showed 5 year survival. 
CONCLUS I ChJS. 
The practical conclusions from this study are these: 
-Rappaport's cytological and structural subclassifications have prognostic 
va!ue. 
-the Ann Arbor staging criteria, 'tihich have been developed for Hodgkin's 
lymphoma, are also valid for the other lymphomas. 
- there is a higher tendency to unpredictable spread than in Hodgkin 1 s disease; 
there are Indications that this spread is more often hematogenous. 
-spread from primary nodal localizations mostly occurs via the lymphatic 
channels; this is not as clear in the case of primary organ localizations; 
striking is the mediastinal skipping during spread. 
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-the chance at obtaining a complete remission gets smaller at each relapse. 
The therapeutic imp I ications are the following: 
Optimal staging is necessary. A staging scheme has to be followed 
systematically to the end, unless a definitive stage IV has been reached 
before. The staging procedure is as follows: physical examination including 
inspection of Waldeyer's ring; X-ray studies: chest (anterior, transverse, 
tomography), lymphangiography, skeletal survey; I iver biochemistry, I iver 
and spleen-scanning; two bone biopsies; liver biopsy: percutaneous or during 
laparoscopy (in this case aspiration of the spleen should be perforMed as 
wei I); exploratory laparotomy with splenectomy (scheme E.O.R.T.C.-trial, 
spring, 1975). As the fate of the patient is decided by the first treatment, 
this has to be optimal. For the lower stages this means intensive mega-
voltage irradiation. The practical use of elective irradiation of adjacent 
lymph nodes is as yet unclear, and has to be evaluated in clinical trials. 
If prophylactic irradiation of adjacent lymph nodes is given, the mediastinum 
can be skipped. It is useful to evaluate the effect of some years of 
chemotherapy after irradiation in patients with stage I and higher. 
Treatment in a specialized centre is desirable because of the dangers of 
aggressive treatment and because of the comp I i cated i nvesti gati on techniques. 
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XIII. SAMENVATTING EN GEVOLGTREKKINGEN. 
HOOFDSTUK EEN geeft een korte inleiding. 
Er wordt een para I lei getrokken tussen ziekte van Hodgkin en de 
andere lymphomen. Een aantal problemen wordt gesteld om te trachten deze 
met de bij de ziekte van Hodgkin zo succesvol gebleken methodieken op te 
lassen. 
HOOFDSTUK HIEE geeft een overzicht over de verzamel ing en verwerking van 
de gegevens afkomstig van 314 patienten met maligne lymphomen uit het 
Rotterdams Radio-Therapeutisch lnstituut. Zij vormen §§n derde van de 
patienten met een maligne non-Hodgkin's lymphoom uit de jaren 1950 tot 
en met 1971. De originele histologische coupes van iedere patient zijn 
herbeoordee I d en gerec I ass if i ceerd vo I gens Rappaport. De k 11 n i sche en 
therapeutische gegevens omtrent de eerste drie aanval len der ziekte 
(Appendix BJ zijn overgebracht op ponskaarten. De kl inische stagering is 
verricht volgens de criteria van de Ann Arbor conferentle. De afsluitings-
datum van de studie is september 1973; dit resulteert in een minlmale 
vervolg periode van twee jaar en zeven maanden. Met speciaal ontwlkkelde 
computerprogramma's (Appendix C) zijn kruistabel len In maximaal zeven 
dimensies gemaakt door een I.B.M. 1130. 
HOOFDSTUK DR IE bespreekt de histologische lndel ing. 
Na een kart hlstorisch overzicht, dat het ontstaan en de betekenis van 
de begrlppen lymphosarcoom en reticulosarcoom schetst, wordt de indel ing 
volgens Rappaport besproken. 
Deze onderscheidt twee structurale mogel ijkheden: diffuus en nodulalr 
(folliculairl. Oak zijn er twee celltypes: lymphocyt en histiocyt, die 
in verschi llende mate van dlfferentiatie voorkomen. 
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Dit resulteert derhalve in vier cytologische types: goed gedifferentieerd 
lymphocytair, weinig gedifferentieerd lymphocytair, histiocytair, histio-
blastair of beter weinig gedifferentieerd histiocytair. Naast de cytologisch 
enkelvoudige tumoren zijn er oak mengvormen. 
In de huidige studie wordt Rappaport's eel indel ing gering gemodificeerd 
toegepast. De equivalenten zijn als volgt: 
L.C.S. = lymphocytosarcoom 
lymphoom. 
L.B.S. 
H.C.S. 
H.B.S. 
lymphoblastosarcoom 
lymphoom. 
histiocytosarcoom 
histioblastosarcoom 
: Rapp : goed gedifferentieerd lymphocytair 
Rapp 
Rapp 
Rapp 
weinig gedifferentieerd lymphocytair 
histiocytair lymphoom. 
histiocytair, weinig gedifferentieerd. 
Diffuus gemengd wordt beschouwd als lymphocytair. 
Foil iculair gemengd wordt apart bezien; deze classificatie is aileen gebruikt 
indien lymphocyten en histiocyten gelijkelijk aanwezig waren. Aile gradaties 
van nodulariteit zijn tesamen gevoegd. 
Een probleem bij de retrospectieve beoordel ing is een vermoedel ijke 
onderpresentatie van de folliculaire variant, omdat de beoordeling is 
verricht zonder de hiervoor soms noodzakel ijke speciale reticul inekleuringen. 
De huidige visie over bouw en functie van de normale lymphekl ier wordt 
besproken. Deze weerspreekt in een aantal opzichten de idee8n van Rappaport. 
De lymphekl ier bevat dendritische macrophagen, gewone macrophagen, 
T-lymphocyten en de 8-lymphocyten-derivaten. Uit de 8-lymphocyt ontwikkelen 
zich na anti gene stimulatie in het tal I ike I centrum de grotere immunoblasten, 
via een tussenstadium van 11 cleaved-cell''; later kunnen zij zich verder tot 
plasmacellen ontwikkelen. 
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Van de vroegere reticulufllcelsarcor:en bl ijft slechts '-'1einig over. 
Deze groeo bl ijkt nu te bestaan uit tumoren van transformerende lymphocyten, 
dendri ti sche reti cuI umce I I en, en wei ni g ged i fferenti eerde f '; brob I as ten; 
oak zijn kl iermetastasen van anaplastische carcinomen vroeger vaak a is 
zodanig beschouwd. Deze idee§n zijn ontstaan naar aanlelding van studies 
met immunologische cel-merkers, enzymcytochemie, electronenmicroscopische 
en vooral oak zorgvuldige I ichtmicroscopische observatie van aile stadia van 
de transformerende I yrnphocyt. 
Over een nieuwe en zinvoller indeling zijn de pennen nag druk in 
beroering. 1/ermoedel ijk ontstaan de foil iculaire lymphomen uit de 
B-lymphocyten in de kiemcentra of uit hun derivaten, de 11 cleaved 11 en 
11 non-cleaved 11 folllkelcentrum eel len. De diffuse lymphomen kunnen uit 
B- of T-lyMohocyten ontstaan. Hierover bestaat nog geen communis opinio. 
De echte reticuluPKelsarcomen zijn gering in aantal - zo zij al bestaan. 
Oak de pathogenetische mechanismen zijn nag gedeeltel ijk duister. 
~~eest rmarschijnlijk is een combinatie van viraal infekt en iMmuungenetische 
voorbeschikking. Dit ontketent de Maligne ontaarding, bij voorbeeld door 
blokkade van de verdere normals ontwikkel ing of door deoressie van bepaalde 
ontvlikkelingsstadia. lmmunologische mechanismen spelen een zeer grate rol 
gezien de hoge frequentie van maligne lymphomen bij patienten, die behandeld 
worden met immuunsuppressiva. 
HOOFDSTUK VIER geeft een overzicht over de histologische en kl inische 
aspecten en verge I ijkt deze met gegevens uit de I iteratuur. 
De voornaamste klachten blj presentatie zljn (pijnlozel kl ierzwel I ing, 
K.N.O.-problemen, en buikklachten; oak huidklachten zijn relatief frequent. 
In 25% zijn er constitutionele symptomen. 
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De tumorlocalisatie biJ presentatie is in 85% nodaal, en in 42% 
uitsluitend nodaal. Van deze kiieren zijn de halsklieren de belangrijkste, 
daarna komen in aflopende volgorde axi I lair, med"tastinaal, !nguinaal, m: It, 
abdomi naa I. Bi j de mi nder vaak voorkomende extra nod a I e I oca I i sati es in de 
volgorde: huid, maagdarmstelsel, luchtwegen, beenmerg. 
De local isaties in stadium I zijn apart beschouv1d, omdat het bij een 
totaal overzicht van al le aangedane plaatsen niet nate gaan is waar de 
oorsprong van het iymphoom is. De local isaties in stadium I geven wei de 
oorsprong van de tumor aan. Ook hier bl ijkt de sterke overheersing van ae 
lympheklieren- met name die van de hals, en tevens dezelfde relatieve 
vo I gorda van de orgaan I oca I i sati es. 
De verde I i ng der k I in i sche stadia toont een onverk I aard da I in 
stadiurr Ill. De histologie valt uiteen in celtype en structuur. Jc1annen 
en vrou, .. :en zijn gel ijk verdeeld qua eel type, doch de diffuus gestructureerGe 
categorie bevat meer mannen. De frequentie der celtypen is L.C.S. 27 %, 
L.B.S. 39 %, H.C.S. 19 %, !-LB.S. 12 %, F.H. 2 %. Het L.C.S. is in 40% 
foil iculair, de anderen zijn overwegend (83- 93 %) diffuus van structuur. 
Macrophagen zijn aanwezig in 10 %. 
Vijf % der oatienten ontwikkelt na de diagnose van het maligne lymphoom 
nag een tweede tumor; het betreft voornamel ijk patienten met een lymprwcytair 
lyr",phoom. De helft dezer tweede tumoren zijn huidcarcinomen. Het is niet 
zeker of de kans op een tweede tumor verhoogd is bij patienten met een 
maligne lymphoom. 
Beenmergaspiratie is in 38% verricht; het resultaat is in 21 % hiervan 
positief. Bij diffuse lymphomen is de frequentie van beenmerginfl ltratle 
duidel ljk hager. Het zij opgemerkt dat volgens de huidige inzichten de 
intensiviteit en technlek der aspiraties voor verbetering vatbaar zijn. 
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Er is geen verschi I tussen mannen en vrouwen wat betreft de freq~entie 
van maligne lyrnohoMen. De leeftijdsverdelingscurve toont bij beiden een 
overwegen der latere decaden, doch de gemiddelde leeftijd van vrouwen is 
lets roger (55 versus 52 jaar). 
HOOFDSTUK VIJF bespreekt de relatie van celtyoe, structuur, ori~aire 
local isatie, constitutionele symptomen en leeftijd. 
De foil iculaire structuur is weinig frequent(+ 10 %l behalve bij 
het L.C.S. {L:.Q %l. In Ieder stadium komt een nagenoeg gel ijk percentage 
fo I I I cuI air voor. 0 it houdt in dat het fo I I i cuI a ire I yrnphoom even aggress i ef 
is als het diffuse, omdat waarschijnl ijk anders het aggressievere type in de 
hogere stadia zou hebben overheerst. Ooval lend is de I age frequentie van 
stadium Ill; dit geldt voor aile celtypes en is oak onafhankelijk van de 
structuur. Het i ivikt alsof aile tyoen lymphoom dit stadium overslaan, en 
zich snel r~itzaaien- 'h'carschijnlijk haematogeen. Dit is duidelijk anders 
oij de ~l:orbus Hodg~in . 
. A.Ihoev .. 'el de geriddelde ieeftijd voor aile celtyoes gel ijk is, komen 
de histiocytaire tyoes zelden voor beneden de twintig jaar. De leeftijds-
verdelingscurve gelijkt op die van de rreeste soliede tumoren en heeft niet 
de bimodale vorm van die der Vorbus Hodgkin. Binnen iedere leeftijdsgroep 
(decade l is de onder I 1 nge verhoud i ng der stadia vri J'-•Ie I stab 1 e I, 
Geen enkel celtype toont een verhoogde neiging tot een uitslultend 
extranodale start; de frequentie is bij allen rand de 13 %. 
Constitutionele symptomen nemen toe naarmate het kl inisch stadium 
stijgt. Het percentage is in Ieder celtype vrijwel gel ijk. Derhalve zijn in 
Ieder celtype de patienten met constitutionele symptomen geconcentreerd 
in de hogere stadia. 
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HOOFDSTUK ZES bespreekt de verschi llende behandel ingswijzen en de 
resultaten. 
Locoregionale lymphomen, d.w.z. stadium I en II al dan niet met 
constitutionele symptomen, zijn bestraald; soms is tevens chirurgie toege-
past. ~1eer uitgebreide lymphomen zijn behandeld met chemotherapie; al dan 
niet met locale hulo van radiotherapie of chirurgie. De radiotherapie heeft 
in de begin jaren bestaan ult voornamel ljk orthovoltage; later is mega-
voltage toegepast. Bij sommige megavoltage bestral ingen zljn oak het 
omliggende gebied of de volgende klierstations proohylactisch bestraald. 
Chi rurg i e is 1ve I i swaar b i j 10 % van a II e behande I i ngen toegepast, doch 
meestal oall iatief; enkelvoudige en curatief opgezette chirurgie vormt 
slechts 3t %. De chemotherapie is voornamelijk enkelvoudige middelen: 
alkylerende stoffen, corticosteroiden, procarbazine, vinca-alkaloiden. 
Van aile patienten- minimum follow-up bijna drie jaar- sterft 66% 
door de tu~or; 21 % is (nog?l in een complete remissie. De drie en vijf 
jaarsoverleving zijn 37 en 25 %. 
De kans op een complete remissie is na de eerste behandel ing het 
grootst; deze moet dan ook in oozet maximaal zijn. 
l'.!aarmate de bestral ing intenser 1.;ordt qua dosis en veldgrootte, neemt 
de kans op complete remissie toe: orthovolt 50%, megavolt 65 %, megavolt 
met electieve bestral ing van om I iggende vel den 74 %. Het zij l'.'el opgemerkt 
dat de orthovolt is gegeven in een vroeger tijdvak, waarin de stagering nag 
niet zo verfijnd was. Chlrurgie wordt in een enkel zeer geselecteerd geval 
als enige therapia toegepast: exisie van een totaal locale tumor. Het heeft 
dan een redel ijk succesfrequentie: 83 % complete re~issie. Chemotherapie is 
weinig succesvol: 18% complete remissie. 
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Bij aile celtypen 't~ordt in 50 tot 60% na de eerste behandel ing een 
cornolete remissie bereikl"i de bovengrens wordt gevormd door L.B.S. en 
H.B.S. De duur evenwel van de comolete remissie is duldel ijk korter bij de 
histiocytaire celtypes en bij de diffuus gestructureerden. Derhalve is de 
qual iteit van de eerste complete remissie, gezien als het product van 
frequentie en duur, het slechts bij de diffuse histiocytaire lymohomen. 
Er is geen duidel ijke relatie tussen de duur van de eerste en tweede 
complete remissie. 
Locale recidieven ontstaan vaker en Sneller bij de histiocytaire 
ly~phomen. In diffuse typen treedt het locale recldief wei I lswaar snel ler 
oo} doch het slot aantal is gel ijk bij de foil iculaire. Een relatie tussen 
locaal recidief en bestralingsgegevens is niet bestudeerd. 
HOOFDSTUK ZEVEN besoreekt de schadel ijke bijwerkingen van de behandel ing 
en de infekties. 
Schadel i jke bi jv1erkl ngen van de behandel i ng zi jn wei haast onvermi jdel i jk, 
omdat deze ~instens even aggressief moet zijn als de ziekte. In deze studie 
ondervindt 41 % der patienten dit. Meest voorkomend zijn beenmergdepressie, 
ulceraties, neuritiden, en corticosteroideffecten. Neuritis is voorgekomen 
b 1 j a I I e pati en ten we Ike vi ncaa I ka I o i den gebru i kten. Corti costero 1 deffecten 
bij 40 % der gebruikers hiervan. Haemorrhagische cystitis bij 33 % der 
cyclophosphamide gebruikers. 
In twaalf patienten, d.w.z. 4% van het totale bestand, heeft de 
behandeling de levensduur duidel ijk verkort. 
lnfekties komen zeer gemakkel ijk voor bij dit type patlenti er zijn 
vele oorzaken: verminderde immuun- en ontstekingsafweer, abnormale I ichaams-
flora, doo:broken anatomische barri8res. 
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Van de patienten heeft 22% een infektie doorgemaakt. Meest frequent 
is het bacteriijle infekt; herpes zoster en opportunistische infekties spelen 
een kleine rol. Dit laatste mogel ijk omdat de diagnostiek van dezen in de 
studieperiode nog moeizaarn was. 
HOOFDSTUK ACHT bespreekt het relatief belang van factoren met prognostisc:he 
invloed. 
De overleving is uitgedrukt als overlevingskans per jaar volgens de 
methode van Kaplan en Heier. Deze actuari€\le methode maakt het f'IOgel ijk ten 
vol le profljt te trekken uit partiijle data, welke een studie als deze altijd 
oplevert. lrrmers de to: low-up is verschi I lend en kan bij sornrnigen nog te 
kart zijn om de valle effecten van de ziekte te kunnen zien. 
r\an de I iteratuur zijn een aantal zorJeheten prognostische faktoren 
ontleend. Elk dezer is apart afgezet tegen de overleving om zijn invloed 
nate gaan; tevens is de correlatie coefficient berekend. 
Klinisch stadium blijkt het belangrijkst (correlatie co€\fficient 0.34), 
op de voet gevolgd door het aanwezig zijn van constltutionele symptomen 
(0.31). Celtype en structuur volgen op enige afstand (0.15 respectievelijk 
0.14). De prognostische volgorde der celtyoen is als volgt: F.M., L.C.S., 
L.B.S., H.B.S. en H.C.S. De diffuus gestructureerde lymphomen hebben een 
mindere orognose dan de folliculaire. 
Er gaat slechts een vrij rnatige prognostische invloed uit van leeftijd 
bij presentatie (0. 1 l),aanwezigheid van macrophagen (0.1 1 }, geslacht (0.09), 
beenmerginvasie (0.08) en het felt of de tumoral dan niet nodaal begint 
(0. 041. 
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~OOFDSTUK NEGEN besoreekt de interdependentie der prognostische faktoren. 
Omdat sommige prognostische factoren nauw verbonden zijn ~et anderen 
- ja zelfs hieruit afgeleid - is het zinvol om voor de totale prognose 
per individuele patient het effect van allen tesaMen te beschouwen en er 
dan de meest belangrijke van de hele groep uit te hal en voor het dagel ijks 
gebruik. Dit is gedaan middels een multiple regressie-analyse. 
~et bl ijkt dat met de beschou,,.;ing van slechts kl inisch stadium, 
aanwezigheid van constitutionele symptomen, en celtype al 93% van de 
totale crognose mogel ijk is. Beziet men hier de aanwezigheid van macro-
phagen ook bij dan looot dit op tot 96 %. Structuur, leeftijd, geslacht, 
beenmerginvasie en extranodale start bl ijken vrij onbelangrljk in het 
gehele beeld. 
hOOFDSTUK TIEr~ besoreekt de wijze van uitzaaiTng. 
Uitgaande van stadiul'l I bij eerste presentatie is de verspreiding 
bij de eerste relaps bestudeerd. Blj de prlmalr nodale presentatles is er 
een zeer sterke tendens tot ordel ijke verspre1ding via de lymphebanen naar 
de volgende lymphekl ierstations. Daarentegen tonen de prima ire orgaan-
local isaties deze tendens zeker niet. Dit kan een argument zijn om bij 
prinair nodale presentatie de volgende klierstations oak te bestralen. 
Het mediastinu~ wordt in een zeer hoog percentage overgeslagen als 
de tumor uitzaaiTng het diaphragma passeert. De lymphocytaire typen hebbem 
lets meer neiging het mediastinu~ tach aan te tasten dan de histiocytaire; 
verschi I in structuur heeft geen invloed. Gezien deze tendens tot overslaan 
van het mediastinum is bestral ing hiervan niet zinvol als prophylactische 
maatrege I . 
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YOOFDSTUK ELF bespreekt het voorkomen van leukemische uitzaaiing; tevens 
komen enkele prima ire orgaanlocal isaties aan de orde. 
De lyMPhosarcoomcel leukemie onderscheidt zich op cytologische gronden 
van de chronische lymphatische leukemia. Zestien patienten hebben of krijgen 
in deze studie een leukemische uitzaaiing van hun lymphocytair of lympho-
blastair lymphoom; in 90 % heeft het oorspronkel ijke lymphoom een diffuse 
structuur. De verschijningstijd van de leukemische uitzaaiing is steeds 
minder dan een jaar. De levensduur na de leukemische uitzaaiing is ongeveer 
vier maanden- iets Ianger biJ de leukemisch uitgezaaide toll iculaire 
lyrnphomen. 
Een patient met een stadium I histioblastosarcoo~ had reeds jaren 
tevoren een rustige chronische lyMphatische leukemie; hij stierf op hoge 
leeftijd aan een hart infarct. Waarschijnl ijk is dit samenval len van twee 
lymphatische tumoren een toeval. 
Van sommige prima ire orgaanlocal isaties is beschreven, dat zij een 
gunstiger prognose hebben. In deze serie is de overleving van enkele van 
deze genoernde spec i a I e ge I oca I i seerde geva I I en verge I eken met die voor a I I e 
gelocal iseerde lymphomen; d.w.z. aile stadia I en II tesamen. De overleving 
van primaire lymphoMen van zowel huid als K.N.O.-gebied (minus Waldeyer's 
ring) Is zeker niet beter. Mogel ijk is hij zelfs lets minder, doch de klelne 
totale aantallen staan geen exacte uitspraak toe. Van de primaire gastro-
intestinale lymphomen, waar overigens de diagnose nooit pre-operatief is 
gesteld, hebben die uitgaande van dunne en dikke darm een lets betere 
respectievel ijk slechtere prognose dan gemiddeld. Evenwel, omdat ook hier 
de totale aantallen zeer klein ziJn is deze uitspraak vrij1vel aileen 
anecdotisch. 
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De prinaire maaglymphonen, elf in getal, zijn chirurgisch bshandeld 
Met ultvoerige nabestral lng. Hier is de overleving duidel ijk verhoogd 
t.o.v. de stadiumgenoten: na vijf jaar meer dan 70 %. 
CONCLUSIE 
De praktische gevolgrekkingen uit deze studie zijn: 
-de cytologische en structurale subclassificaties van Rappaport geven 
reEile prognostische informatie. 
-de voor de Morbus Hodgkin ontwikkelde fl,nn Arbor stadium indel ing is oak 
voor de andere I ymphomen zeer we I bru i kbaar. 
- er is een grotere neiging tot onvoorsoelbare uitzaaling dan bij de 
Morbus f-''odgkin; er zijn aan111 ijzingen dat deze oak vaker haematogeen is. 
-de verspreidlng vanuit primalre klierlocalisatles verloopt meestal via 
lymphebanen; Dij orimaire orgaanlocal isatles is dit vee I minder duidel ijk; 
opvallend is het overslacn var het Medicstinum (mediastinal skipping) 
tijdens de verspreiding. 
-de kans op complete remissie wordt bij elk recidief kleiner. 
De therapeutlsche imol icaties zijn: 
Ootimale stadiumindeling is noodzakelijk. ~~en dient systematisch een 
stageringsschema te volgen tot het einde, tenzij tevoren reeds definitief 
een stadiu'" IV bereikt wordt. Dit schema is als volgt: lichamelijk onder-
zoek inclusief inspectie van \·'laldeyer's ring; rOntgenonderzoek: X-thorax 
(VA, O',,l, to(\lograrn), lyrnohangiographie, skeletoverzicht; uitvoerige lever-
chernie, lever- en mi ltscintigrafie; 2 x botboring; leverbiopt per-cutaan of 
laparoscoop {dan tevens mi ltbiootl; proeflaparotomie met splenectomie 
{zie schema E.O.R.T.C. trial, lente 1975). 
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Daar het I ot van de patient bes I i st wordt door de eerste behande I i ng moet 
deze optiMaal zijn. Dit betekent voor de lagere stadia een intensieve 
megavoltage bestral ing. Het nut van prophylactische bestral ing van aan-
grenzende kl ierstations is nog onduidel ijk, en dient nog eevalueerd te 
worden in kl inlsche trials. Zo er tach proohylactlsche bestral ing der 
aanl iggende kllerstatlons wordt verricht dan kan het mediastinum hierbij 
worden overgeslagen. Het is zinvol om bij patienten in stadium I, en 
zeker bij patlenten met hogere stadia, het effect van enige jaren chemo-
theraple na de bestral ing te evalueren. Vanwege de grate gevaren door de 
aggress i eve behande I i ng en vanwege de gecomp I i ceerde onderzoekmethod i eken, 
is behandel ing in een gespecial iseerd centrum wensel ijk. 
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I - 3 
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10 - 16 
16 - 22 
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23 - 29 
29 - 35 
35 - 41 
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42 - 48 
48 - 54 
54 - 57 
57 
58 
CODE ON OPTICAL READING CHART AND PUNCHCARDS 
INTERPRETATION 
CARD-NUMBER 
PATIENT F I LE-NW~BER 
INSTITUTE CODE 
PATHOLOGY FILE-NUMBER 
CYTOLOGY FILE-NUMBER 
SEX M " MALE , F " FEMALE 
BIRTHDATE - INVERTED I: YEAR, MONTH, DAY) 
DATE OF FIRST SYMPTm1S - INVERTED 
DATE OF PATHOLOGY DIAGNOSIS - INVERTED 
INSTITUTE OF DIAGNOSIS 
DATE OF PRESENTATION AT INSTITUTE - INVERTED 
DATE OF DEATH, I IF KNOWN) - INVERTED 
SURVIVAL IN MONTHS AT CLOSING-DATE 
CONDITION AT CLOSING-DATE 
D deceased 
D by tumor 
2 D 2 by other iII ness 
3 D 3 iatrogenic campi ications 
4 D 4 cause unknown 
5 LC alive, complete remission 
6 LIC alive, partial remission 
7 L? alive, remission unknown 
9 : ? no fo I I ow-up 
NUMBER OF REMISSIONS ATTAINED 
- 1 37 -
Appendix 6 
Card no. 1, continued Appendix 8 
NO. ON CARD 
59 
60 
61 
62 
63 
64 
65 
66 
67 
68 
69 
70 - 73 
73 - 75 
75 
76 - 79 
79 - so 
Card nr. 2 
I - 2 
3 - 9 
INTERPRETATION 
COMPLICATIONS 
LUNGFIBROSIS - PNEUMONITIS 
DERMATITIS 7 positive 
BONE-MARROW DEPRESSION 
STEROID SlOE EFFECTS 
HAEMORRHAGIC CYSTITIS 
NEURITIS 
INFECTION, UNCLASSIFIED 
8 negative 
9 unknown 
VIRTUAL FOLLOW-UP (ACCORDING TO KAPLAN I 
INFECTION: 2 +, 3"'-, 4"" bacterial, 5 viral (minusherpes), 
6 = herpes, 7 ooportunistic, 9 = unknown 
LEUKEI~ I A 7 + , 8 = - , 9 = unknown 
INTERVAL IN MONTHS FROM PRIMARY THERAPY Tl LL LEUKEMIA-APPEARANCE 
LEUKEMIATYPE IN CODE 
RECURRENCE IN IRRADIATED AREA 7 central, 8 peripheral, 
9 = unknown 
INTERVAL IN MONTHS BETWEEN IRRADIATION AND RELAPSE IN IRRADIATED 
AREA 
AGE IN YEARS 
CARD NUMBER 
FILE NUMBER 
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Card no. 2~ continued 
NO. ON CARD 
9 - I 0 
II 
INTERPRETATION 
FIRST COMPLAINT 
none 
2 painless lymphnodes 
3 pa i nfu II I ymphnodes 
4 gastrointestinal complaints 
5 fatique, malaise 
6 fever, night-sweats 
7 bone pain 
8 unexplained weight loss 
9. E.N.T.-problems 
11 vena cava superior syndrome 
12 respiratory tract abnormalities 
13 Unknown 
14 skin manifestations 
15 salivary gland abnormalities 
16 urogenital symptoms 
17 ~ muscle weakness 
HISTOLOGY 
sma I I-ce II 
2 polymorph-eel I 
Lymphoblastosarcoma 
3 medium sized eel I 
4 large tell 
5 histiosarcoma 
6 histioblastosarcoma 
7 polymorph-eel I histiosarcoma 
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Card no. 2, continued Appendix 6 
NO. ON CARD INTERPRETATION 
II HISTOLOGY 
8 mixedfollicular 
9 no ma I i gnant I ymphoma 
i2 NECROSIS 
none 
2 pas i ti ve 
3 grade 
4 grade II 
5 grade Ill 
9 unknown 
13 PRESENCE OF MACROPHAGES 
none 
2 grade 
3 grade II 
4 grade Ill 
9 unknown 
14 QUALITY OF S L I OES 
good 
2 poor 
3 rather sma II 
4 2 + 3 
5 wrong s I ide? 
9 no opinion possible 
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Card no. 2, continued 
NO. ON CARD 
15 
16 
17 
18 
INTERPRETATION 
PRESENCE OF EPITHELOID CELLS 
none 
2 few 
3 many 
9 no opinion possible 
STRUCTURE 
diffuse 
2 foil icular, well structured 
3 fol I icular, poorly structured 
4 partial follicular 
5 foil icular, deposits of eosinophi I ic material 
6 mixed foil icular = 11.8 
9 no opinion possible 
FIBROSIS 
none 
2 nodular fibrosis 
3 band I ike fibrosis 
4 hyaline fibrosis 
5 2 + 4 
6 diffuse fibrosis 
8 positive, no further 
9 no opinion 
ORIGIN 
lymph node 
2 extranodal 
3 1 + 2 
possible 
score 
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Card no. 2, continued 
NO. ON CARD 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
INTERPRETATION 
ORIGIN 
4 bone-marrow 
5 post mortem 
9 unknown 
EOSINOPHILIC CELLS 
none 
2 few 
3 many 
9 no oo inion 
CYTOLOGY 
OTHER I~A L I GNANCY 
0 no 
positive, exceot skin 
6 skin 
9 unknown 
L Y'IPH NODES 
NECK, TOTAL, LEFT 
NECK, TOTAL, RIGHT 
CERVI CAL, LEFT 
CERVICAL, RIGHT 
SUB'~AND I BU LAR, LEFT 
SUB'-IAND I BU LAR, RIGHT 
2 
8 
9 
clinically positive 
negative 
histology positive 
unknown 
ANTERIOR CERVICAL TRIANGLE, LEFT + Ccl inical lyl 
ANTERIOR CERVICAL TRIANGLE, RIGHT 2 
SUPRA- AND INFRACLAVICULAR, LEFT 8 PA + 
SUPRA- AND I"NFRACLAV I"CULAR, R I·GHT 9 ? 
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Card no. 2, continued 
;-.JQ, ON c,..;po 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
I NT~RPRET.A. T I Cm 
"'-.X! LLARY, L.EFT 
AX 1 LLARY ~ RIGHT 
INGUINAL, !_EFT 
INGUINAL, RIGHT 
VJA LDEYER 
''lED I AST I NUH 
SPLEEN 
IVJESENTER I c 
P?,R;\-AORT,A.L, LEFT 
PARA-AORTA.L, RIGHT 
LUI~BAR, LEFT 
LUMBAR, RIGHT 
BICEPITAL, LEFT 
BICEPITAL, RIGHT 
POPLITEAL, LEFT 
POPLITEAL, RIGHT 
ORGANLOCALIZATIONS 
UPPER RESPIRATORY TRACT 
ESOPHAGUS 
STOIIACH-DIJODENUM 
SI4ALL INTESTINE-APPENDIX 
COLON-RECTUM 
LIVER 
BILIARY TRACT 
SKIN 
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+ (cl inicallyl 
2 
3 PA + 
9 ? 
Card no. 2~ continued 
NO. ON CARD 
56 
57 
58 
59 
6D 
INTERPRETATION 
SKELETON 
positive 
2 negative 
3 central skeleton 
4 upper leg 
5 I ower leg 
6 upper arm 
7 lower arm 
8 sku I I 
9 unknown 
LUNG 
PLEURAL EXSUDATE 
positive, no cyto I ogy known 
2 negative 
5 positive, cytology 
6 positive, cyto I ogy 
9 unknown 
SAL I VARY GLANDS 
c I i n i ca I I y positive 
2 negative 
8 histology positive 
9 unknown 
ENDOCRINE GLANDS 
positive 
2 negative 
negative 
positive 
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Card no. 2, continued appendix B 
NO. ON CARD INTERPRETATION 
60 ENDOCRINE GLANDS 
4 thyroid gland 
5 adrenal glands 
9 unknown 
61 UROGEij I TAL SYSTEM 
positive 
2 negative 
4 kidney 
5 ureter- bladder 
6 penis - prostate -vagina - uterus 
7 testis- ovary 
9 unknown 
62 OTHER EXTRA-NODAL 
63 LYMPHANGIOGRAPHY 
A+l-
2 A -l + 
3 A L 
• • 4 A L 
8 suspect 
9 not performed 
A para-aortic 
L para-1 umba I 
64 RADIOLYMPHANGIOGRAPHY !CODE SEE' 631 
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Card no. 2, 
NO. ON CARD 
65 
66 
67 
68 
69 
70 
71 
72 
73 
74 
75 - 80 
Card nr. 3 
I - 2 
3 - 9 
continued Appendix 8 
INTERPRETATION 
BONE-MARROW BIOPSY positive 
BONE-MARROW ASPIRATION 2 negative 
8 suspect 
9 not performed 
LIVER SCAN positive 
SPLEEN SCAN 3 negative 
8 suspect 
9 not performed 
CLINICAL STAGE I - II - Ill - IV , IV with leukemic phase 
SYSTEMIC SYMPTOMS 
A 
2 B 
PRIMARY LOCALIZATION 
2 nod a I 
3 extra nodal 
4 both 
5 leukemic phase 
PATHOLOGICAL STAGE I - II - Ill - IV, IV with leukemic phase 
LAPAROTOMY 
LAPAROSCOPY 
CARD NUMBER 
FILE NUMBER 
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oerformed 
2 not performed 
9 unknown 
Card no. 3, continued 
NO. ON CARD 
9 
10 
II 
12 
13 
14 - 20 
20 
21 
22 
23 
24 - 27 
27 - 28 
28 - 30 
30 - 34 
INTERPRETATION 
HEMOGLOBINE 
LEUKOCYTES 
E .S .R. 
S.G.P.T. 
SERUM ALKALINE PHOSPHATASE 
INSTITUTE OF TREATMENT 
SURGICAL TREATMENT 
done 
2 not done 
9 unknown 
RADIOTHERAPY 
orthovoiTage 
2 megavoltage 
lowered 
3 normal 
5 raised 
9 unknown 
3 megavoltage + wide field prophylaxis 
4 none 
9 unknown 
CHEMOTHERAPY 
yes 
2 no 
IRRADIATION DOSE IN RAOS 
NUMBER OF IRRADIATIONS 
IRRADIATION TI~~E IN DAYS 
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Card no. 3, continued Appendix B 
NO. ON CARD INTERPRETATION 
34 - 35 FIRST CHEI10THERAPY adri amyci n 
36 - 37 SECOND CHEMOTHERAPY 2 BCNU 
38 - 39 THIRD CHEI~OTHERAPY 3 bleomycin 
4 CCNU 
5 corticosteroids 
6 cytosine arabinoside 
7 rubidomycin 12 methotrexate 
8 eye I ophoso ham ide 13 busulfan 
9 chlorambucil 14 orocarbazin 
10 methy 1-CCNU 15 vi ncri sti n 
II nitrogen-mustard 16 thiotepa 
17 vinblastin 
18 ACOP 
22 MOPP l pulse dosage 
23 MABOP 
19 COP, continuous 24 mercaptopurin 
20 COP l pulse dosage 
21 COPP 
25 triethylene melamine 
26 urethane 
39 - 46 RESULT OF TREAmENT 
complete remission 
2 partial remission 
3 failure 
4 non-evaluable 
9 unknown 
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Card no. 3, continued Appendix B 
NO. ON CARD 
47 - 50 
50 - 53 
>53 
INTERPRETATION 
INTERVAL IN MONTHS BETWEEN PRIMARY TREATI~ENT AND RELAPSE 
INTERVAL IN MONTHS BETWEEN TWO SUCCESSIVE MANIFESTATIONS OF 
DISEASE 
Note: All open numbers can be fi lied in with further data 1 
if necessary. 
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Appendix C 
PROGRAMS USED FOR cm~PUTING AND STATISTICAL ANALYSIS. 
A. INTRODUCTION. 
All programs are especially developed for this study. However, they 
are designed in such a way that it is easy to add more patients and episodes 
of the disease, that may have occurred after the closing date. The checking 
programs make it possible, by I imiting the permitted values, to retain only 
the correct data; all punchcards showing fi I ing errors or logical deficiencies 
are put apart for correction. Filing errors are omissions of important 
data, such as length of follow-up or result of treatment. Logical deficiencies 
are present when impossible results are derived from correct data, e.g. 
leukemic development staged as r1. The statistical program produces a 
set of 24 parar;Jeters from the f \ I es of a I I patients, and puts these combined 
data in computer storage. Between any desired pair of these parameters 
cross-tabulations can be made, complete with statistical analysis. 
Furthermore 5 other variables can be 11 frozen 11 into specified positions; 
this makes cross-tabulations in 7 dimensions possible, e.g. radiotherapy 
methods (1) cross-tabulated against treatment results (2) on the basis of 
the following criteria: male (3), more than 30 years of age (4), diffuse (5), 
well differentiated lymphocytic lymphoma (6), stage I or II (7). 
B. CHECKING PROGRAMS. 
2. ON EVen 
3. EVEN 
4. ELLEnde 
checks punchcard number one on logical deficiencies and fi I ing 
errors. 
checks odd numbered cards except for the first card. 
checks even numbered cards. 
checks for missing data cards. 
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5. ZOEK 
6. WENS 
Appendix C, continued 
col Jects alI data cards with a given file number (e.g. a 
patient whose data need correction or updating) and puts 
them apart. 
puts all cards apart that have a specified value at one 
particular place; this is in fact lifting of selecTed files. 
C. STATISTICAL PROGRAMS. 
7. COMP 
8. KRUIS 
puts 24 specified data from each patient in computer storage 
(e.g. disk-storage). From this matrix cross-tabulations are 
made. 
computes cross-tables from specified data campi led by COMP. 
The following side features are incorporated in this program: 
a. 5 11 frozenu dimensions are possible, therefore 7 dimensional 
tabulations can be effected. 
b. this program, unless directed not to do so, calculates with 
each tabulation also the sums, standard error, standard 
deviation, probablility, X-square and L-test; also it 
indicates whether the X-square or the L-test is the more 
useful. To do this some subroutines were used: 
9. GAUS T 
I 0. CHI P 
gives the integral of a Gaussian 
distribution by polynomial approximations 
(I bbetson, 1963). 
uses GAUS T to compute probabi I ities 
CHill and Pike, 1967; O'Brien and Wood, 
1968). 
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12. FREQ 
13. REGR T 
II. CHIP test 
Appendix C, continued 
tests COMP, KRUIS and CHIP together 
against a set of known values (Pearson, 
1962). Besides it tests the decimal 
accuracy of the entire computing system. 
c. correction of the raw survival figures according to the 
I ife-table method of Kaplan and Meier. 
this is a simp I ified version of program KRUIS which presents 
multiple cross-Tabulations in one table- without statistical 
eva I uati on of the resu Its. In effect it cross-tabu I ates a II 
known lor permitted) values of the first X data, against a I I 
known lor permitted) values of the last Z data, for each 
known lor permitted) value of Y; the sum of X, Y and Z is 
maximally 24. 
performs multiple regression analysis after data transformation 
in a way comparable to the I.B.M.-S.S.P. programs (I.B.M., 1(}68). 
- 152 -
Appendix 0: ,ie., Survey or 1-'r-ir'HI'/ l_oc:clizd·l-ions 
---- 1~- ---
r 
~ 
§ I s I H ''" ;:! F.: ((I <{) <l> -P f-'1 H >:: cJ 8 I O+> 
ill >-1 ~ W H f.t ·rl f..< ' E1 ?-. 0 ~ H P P., ~ • P.,UJ "'" H ,..:) ~ 1! -f.l illl 'll ..rj;:J ..rj rl+' H~> [., P., H 'tl rl 
f.< rl ....:! e:; C1l C1l >-. Ul >.! () ?, () ~ l'i (.) ·~ [\j >:: >-. f.( QJ QJ ll) i< l1J Ul ·.-l C1l 
<llrl rlc-!>::>::UJffiUJ.s::1f<fllaJQJ>::;:Jf.t rl ~f..<'drl·.-lUJOJ'r;;!lll~·.-li>.O?'OOr.l 
Ei<tl .Yo ..'<[ •-I rl ·rl ·d '"d ·rl QJ P, OJ;>: 8'0 0+.> UJ ~: rl M)v ;:J:;J <-I·P .; f.>'D ·rl·H +>M <I>H ·rlr.l H (!,) 
cl0 0 U •rl ·rl 0 0 rl '0 ~1 S p,HOOMU,'> ·rl ;:J >::-,0lll<\l<fl '1j <i.l<ll~(lJ}<IlroQHrl<tl i>. H 
f.tO <1> a> K H H <11 QJ ~~ >-. P,·M 4~;:! 0(,) ·rl ,~ ,'), ;:J<il , ... IX"f>O> ~1 l"rl <Dffi <1>? oro ffirl ,.C: 'tl ~ ~ ~ ? '" ~ 0 0 > ~ "'-e-''-- _" '' _ _"'_"_ U ~ -:' I W __ '"__ ele'_ "",'~_ "' P _ ~ ) ~ P -' > H 0 ~ " m 0 H __:'_j 
Tot l,,s 13:7 71 '65 69 62 '77 52
1
46 38 25 
1
17 o 1''~9 
1
,, IK '3 for, 1 , , 7 2'' " 3 2 
st___l_ 11 12 2 1 !1 I:! 4 
--------st" -~--- - -- 2101 0! 0121011 -f-l--j__Q_J 
3 n 'il.J __ 4_'5 _u 11 10 ·12 _3c; 12 2 15 2 ~+--" ~. ·o_l_~lft~ .. L __ Q_I--'--t-i'=W-. 1 
__ pi 27 ~g _L~ 14 20 17 _ '1.._ 11 7 10 j---1 __ j ____ o ... j 
s ~v 50 50 37 35 32 29 21 23 JJ s 1 o 
0 J ·- -·-- +-Q. 0 --,--- L----- --- 0 _Q__l_Q__ _Q_ 0 
,...=-,_-- 1 0 4 18 2 2 
LCS 
LBS 
HCS 
HDS 
FN 
51 47 20 17 22 23 'JJ lJ 16 19 9 10 0 1/ I 15 5 I 'J 
2 r~-~----Of-_0101131211101 
,1 0 3 1 5 6 
J 
47 1:5 21+ ___ 22 _ ~~---~~__2_~- _ _!:;! __ 18 I 0 l_) ___ , _ __. _ 
_2_5__E_ __ ,6 12 12 7 13 9-1-6 ,, ~~I~> o_j,_o_J_'-31_2_61-'1 o ' _ _2_ _o__2_ 
21 20 8 11 3 2 13 6 2 I ') 0 {) 2 ~ 2 r) I I 0 Q 1 0 0 0 0 0 0 
·--; -----·-·- ----I_ -- ---
/1 J 3 3 _____ _!1- -~ o __ 2___ __ !._ o o_ ~- ~- ____:__ o 1__ 1 __ o o ___ o o o 2 o o o 
~~~-;7~3- 44 4J IJ'!. J8--3~27To-~~-11--IO--o- Jo r-;;--) -11--8 J- ,- J_ 0 5 14 I J 1 I LFoJl 3'!_ 27 17 19 19 ___ 18 7 10 16 '10 2 J 0 7 9 t 0 1 6 h 1 0 0 0 0 9 0 1 0 -~- :_~~-=~ ,~2. ~--"~ , J? ==~ 1616 -,,, ~~- 0~1J':'~ _~_t~l ,- _!_8-f_,- ,-~~ '~- 3 o ' 1 
" 
"' 
I CLinicaL stage I I III IV 
nLn All 
I Cell type 
I LCS 18 22 I 1 4 26 
1 
" 
I 84 i I I 
LBS 27 I 49 1 2 I 31 l J 122 I 
HCS 15 I 20 4 22 0 61 HBS 9 I 21 1 6 0 37 
Fl'I 1 1 1 4 0 7 
All 70 11 3 32 89 7 J 11 
.1'\ppendix __ Cell type and Clinical Stage. 
Clinical stage I II III IV All I 
Structure: 
Diffuse 35 66 12 h8 1 61 
Follicular 18 1 9 1 0 1 5 62 
All 53 ss 22 63 221 
i\ppendix F Structure and Clinical Stage. 
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~e LCS LBS HCS tiBS F1-'1 All ~ e 
0 - 20 6 7 0 15 
20 - 40 J 1J 9 6 32 
L,o 
-
60 31 39 18 1 2 0 1 00 
60 
-
80 39 53 26 1 5 6 139 
>so 7 1 0 7 4 0 28 I 
All 86 122 61 38 7 I J 1 L, l 
Appendix G : Ce I I type and age in years l. 
~ I Diffuse Foll.icular All e 
I 0 - 20 7 3 10 I 
I 
20 - 40 20 5 25 
40 - 60 
I 
49 19 68 
l 60 - 80 76 29 105 
! >so I 13 7 20 
I All I 1 65 63 228 
Appendix H Structure and age \in years). 
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Appenx J: The effect of constitutional symptoms vlithin each clinical stage and within each cell type. 
Survival Chance Percentage 
-----~----.. -----
Years Clinical s·t.age 
of I ~~II_I-~-survi 
val A B 
------~--
n:=- 64 J 90 6 16 12 
-~ .. --~~--~-
0 100 I 00 1 00 1 00 "100 1 00 
-
0 0 
1 92 67 69 50 37 so 
2 81 67 49 0 25 33 
J 73 67 44 25 25 
II 65 67 38 19 25 
5 57 33 35 1 2 12 
6 51 33 33 "12 1 2 
0 
7 46 33 30 6 12 0 
8 38 33 27 6 1 2 
-
9 19 33 27 6 0 
1 0 1 9 33 27 6 
1 1 0 33 27 6 
12 0 27 6 
"I 3 21 0 
1 L1 1 4 
15 14 
""" 
Note: Below this sign 0 
Below this sign 
n <10 
n < 5 
Appendix J 
" Histology 
IV LCS LBS HCS HBS 
A B A D A B A B A B 
--------
J 1 39 _:)0 1 9 78 ? ,-~o lfO 1 4 21; 7 
-----
1 oo 1 00 100 I 00 1 00 "100 1 00 1 00 1 00 1 00 
0 0 0 
- -
45 IS 73 47 73 28 65 21 62 14 
- -
39 5 58 32 58 8 47 0 54 14 
-
0 
32 0 56 21 51 If 39 L~ L~ "14 
0 
29 49 1 4 Lj.L~ L, 39 37 14 
0 
25 45 7 }.~ 1 0 34 37 1 4 
25 39 7 _38 31f 37 1 4 
-
20 34 7 38 1 9 37 14 
0 
20 28 7 38 1 9 37 14 
0 
20 25 0 38 19 37 14 
20 22 38 13 37 1 If 
-
1 3 18 38 13 37 14 
"j 3 "18 38 13 37 14 
13 18 0 1 3 37 0 
0 9 0 37 
9 17 
"' 
"' 
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